Myriad Genetics (MYGN) 10-K 28 Feb 25 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Dec. 31, 2024	Feb. 21, 2025	Jun. 28, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	0-26642
Entity Registrant Name	MYRIAD GENETICS, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	87-0494517
Entity Address, Address Line One	322 North 2200 West,
Entity Address, City or Town	Salt Lake City
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84116
City Area Code	801
Local Phone Number	584-3600
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	MYGN
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction	false
Entity Shell Company	false
Entity Public Float			$ 2,221,380,714
Entity Common Stock, Shares Outstanding		91,309,064
Documents Incorporated by Reference	The following documents (or parts thereof) are incorporated by reference into the following parts of this Form 10-K: Certain information required in Part III of this Annual Report on Form 10-K is incorporated from the Registrant's Proxy Statement, to be filed no later than 120 days following December 31, 2024 , for the Annual Meeting of Stockholders expected to be held on June 5, 2025.
Amendment Flag	false
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Entity Central Index Key	0000899923

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2024
Audit Information [Abstract]
Auditor Name	Ernst & Young LLP
Auditor Location	Salt Lake City, Utah
Auditor Firm ID	42

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 102.4	$ 132.1
Marketable investment securities	0	8.8
Trade accounts receivable	121.2	114.3
Inventory	27.5	22
Prepaid taxes	16.4	17
Prepaid expenses and other current assets	30.5	19.4
Total current assets	298	313.6
Operating lease right-of-use assets	55	61.6
Property, plant and equipment, net	117.4	119
Intangibles, net	262.4	349.5
Goodwill	286.3	287.4
Other assets	8.5	15.4
Total assets	1,027.6	1,146.5
Current liabilities:
Accounts payable	32.3	25.8
Accrued liabilities	119	113.9
Current maturities of operating lease liabilities	12.8	16.2
Total current liabilities	164.1	155.9
Unrecognized tax benefits	32.7	30.2
Long-term debt	39.6	38.5
Noncurrent operating lease liabilities	87.9	97.4
Other long-term liabilities	2.2	41.3
Total liabilities	326.5	363.3
Commitments and contingencies
Stockholders’ equity:
Common stock, $0.01 par value, 91.3 and 89.9 shares outstanding at December 31, 2024 and 2023, respectively	0.9	0.9
Additional paid-in capital	1,457.8	1,415.5
Accumulated other comprehensive loss	(0.8)	(3.7)
Accumulated deficit	(756.8)	(629.5)
Total stockholders' equity	701.1	783.2
Total liabilities and stockholders’ equity	$ 1,027.6	$ 1,146.5

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares shares in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares outstanding (in shares)	91,300	89,900	81,200	80,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 837.6	$ 753.2	$ 678.4
Cost of revenue	252.2	236.2	202
Gross profit	585.4	517	476.4
Operating expenses:
Research and development expense	113.4	88.7	85.4
Sales and marketing expense	284.1	289.2	266.8
General and administrative expense	275.9	283.7	247.9
Legal settlements	(21.3)	112.8	0
Goodwill and long-lived asset impairment charges	56.8	0	16.9
Total operating expenses	708.9	774.4	617
Operating loss	(123.5)	(257.4)	(140.6)
Other income (expense):
Interest income	1.7	2.5	2.6
Interest expense	(2.8)	(2.9)	(3.2)
Other	1.1	(4.4)	0.6
Total other expense	0	(4.8)	0
Loss before income tax	(123.5)	(262.2)	(140.6)
Income tax expense (benefit)	3.8	1.1	(28.6)
Net loss	$ (127.3)	$ (263.3)	$ (112)
Net loss per share:
Basic (in dollars per share)	$ (1.41)	$ (3.18)	$ (1.39)
Diluted (in dollars per share)	$ (1.41)	$ (3.18)	$ (1.39)
Weighted average shares outstanding:
Basic (in shares)	90.6	82.8	80.6
Diluted (in shares)	90.6	82.8	80.6

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (127.3)	$ (263.3)	$ (112)
Change in unrealized loss on available-for-sale debt securities, net of tax	0.1	1.2	(2.5)
Reclassification adjustments for losses included in net loss, net of tax	(3)	2.1	(1.3)
Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax	0	1.5	0
Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax	5.8	0.4	0
Comprehensive loss	$ (124.4)	$ (258.1)	$ (115.8)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Common stock	Additional paid-in capital	Accumulated other comprehensive loss	Accumulated deficit
Beginning balance at Dec. 31, 2021	$ 967.8	$ 0.8	$ 1,226.3	$ (5.1)	$ (254.2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax	(4.3)		(4.3)
Stock-based compensation expense	38.1		38.1
Net loss	(112)				(112)
Other comprehensive (loss) income, net of tax	(3.8)			(3.8)
Ending balance at Dec. 31, 2022	885.8	0.8	1,260.1	(8.9)	(366.2)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax	(2.8)		(2.8)
Issuance of common stock for public offering, net	117.6	0.1	117.5
Stock-based compensation expense	40.7		40.7
Net loss	(263.3)				(263.3)
Other comprehensive (loss) income, net of tax	5.2			5.2
Ending balance at Dec. 31, 2023	783.2	0.9	1,415.5	(3.7)	(629.5)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax	(7.5)		(7.5)
Stock-based compensation expense	49.8		49.8
Net loss	(127.3)				(127.3)
Other comprehensive (loss) income, net of tax	2.9			2.9
Ending balance at Dec. 31, 2024	$ 701.1	$ 0.9	$ 1,457.8	$ (0.8)	$ (756.8)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (127.3)	$ (263.3)	$ (112)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	61.2	61.9	52.7
Non-cash lease expense	9.5	11.3	11.7
Stock-based compensation expense	49.8	40.7	38.1
Deferred income taxes	(2.8)	(4)	(30.8)
Unrecognized tax benefits	2.5	3.4	(1.1)
Impairment of goodwill and long-lived assets	56.6	0	16.9
(Gain) loss on termination of lease	(3.1)	7.7	0
Gain on acquisition	(2.2)	0	0
Other non-cash adjustments	1.5	4.4	1.7
Changes in assets and liabilities:
Prepaid expenses and other current assets	(3.7)	0.2	1.6
Trade accounts receivable	(8.7)	(12.5)	(10.3)
Inventory	(6.2)	(1.8)	(2.9)
Prepaid taxes	0.5	0.7	0.7
Other assets	0	0.6	(0.9)
Tenant improvement allowance received	0	16.3	18
Accounts payable	4.7	(3.7)	(3.5)
Accrued liabilities	(41)	27.2	(86.2)
Net cash used in operating activities	(8.7)	(110.9)	(106.3)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures	(19)	(63.2)	(45.3)
Capitalization of internal-use software costs	(10.7)	(10.1)	0
Proceeds from the sale of business, net cash sold	8.8	0	0
Acquisitions, net of cash acquired	0	0	(57.2)
Purchases of marketable investment securities	0	0	(103.2)
Proceeds from maturities and sales of marketable investment securities	9	105.2	128.2
Net cash provided by (used in) investing activities	(11.9)	31.9	(77.5)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from common stock issued under stock-based compensation plans	5.9	6	6.3
Payment of contingent consideration recognized at acquisition	0	0	(3)
Payment of tax withheld for common stock issued under stock-based compensation plans	(13.4)	(8.8)	(10.6)
Proceeds from underwritten public offering, net of costs and discounts	0	117.6	0
Proceeds from revolving credit facility	120	80	0
Repayment of revolving credit facility	(119.5)	(40)	0
Fees associated with issuance and refinancing of revolving credit facility	0	(1.7)	(0.7)
Payment on finance leases	(0.4)	(0.2)	0
Net cash provided by (used in) financing activities	(7.4)	152.9	(8)
Effect of foreign exchange rates on cash, cash equivalents, and restricted cash	(1)	0.6	(0.6)
Net increase (decrease) in cash, cash equivalents, and restricted cash	(29)	74.5	(192.4)
Cash, cash equivalents, and restricted cash at beginning of the period	140.9	66.4	258.8
Cash, cash equivalents, and restricted cash at end of the period	$ 111.9	$ 140.9	$ 66.4

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Financial Statement Presentation Myriad Genetics, Inc. (together with its subsidiaries, the "Company" or "Myriad") is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower health care costs. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. The Company’s principal executive office is located in Salt Lake City, Utah. The accompanying consolidated financial statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (“GAAP”) for financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. Use of Estimates The preparation of the consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, our incremental borrowing rates used to calculate our lease balances, stock-based compensation, purchase accounting, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates. Reclassifications Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, or cash flows from operations. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company limits its exposure to loss by placing its cash in financial institutions with high credit ratings. The Company's cash consists of deposits held with banks that generally exceed federally insured limits of $250,000 per customer. Substantially all of the Company’s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company does not require collateral from its customers. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented approximately 12%, 12%, and 14% of total revenue for the years ended December 31, 2024, 2023, and 2022, respectively. Concentrations of credit risk are mitigated due to the number of the Company’s customers as well as their dispersion across many geographic regions. The Company has only one payor that accounted for more than 10% of accounts receivable at December 31, 2024 and 2023. The balance of accounts receivable from the payor represented 18% and 12% of the total accounts receivable balance as of December 31, 2024 and 2023, respectively. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents primarily consist of cash and money market deposits with financial institutions. Restricted Cash In certain circumstances, the Company is required to maintain cash deposits with certain banks with respect to contractual or other legal obligations, and therefore the use of these cash deposits for general operational purposes is restricted. As of December 31, 2024, restricted cash was approximately $9.5 million, of which $8.6 million was recognized as a current asset and $0.9 million was recognized as a long-term asset. As of December 31, 2023, restricted cash was approximately $8.8 million, of which $1.2 million was recognized as a current asset and $7.6 million was recognized as a long-term asset. The restricted cash amounts are largely comprised of cash held in escrow related to the Company's acquisition of Gateway Genomics, LLC ("Gateway"), which occurred during the year ended December 31, 2022. The current and long-term portions of restricted cash are included in Prepaid expenses and other current assets and Other assets, respectively, on the Consolidated Balance Sheets. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Consolidated Balance Sheets that agrees to the amounts included in the Consolidated Statement of Cash Flows. December 31, (in millions) 2024 2023 2022 Cash and cash equivalents $ 102.4 $ 132.1 $ 56.9 Restricted cash 9.5 8.8 9.5 Total cash, cash equivalents, and restricted cash $ 111.9 $ 140.9 $ 66.4 Marketable Investment Securities The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in Accumulated other comprehensive loss in Stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company’s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash. A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company’s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the years ended December 31, 2024, 2023, and 2022. Inventory Inventories consist of supplies such as reagents, plates, and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard cost, which approximates actual cost on a first-in first-out basis. The Company evaluates its inventories for excess quantities and obsolescence. Inventories that are considered excess or obsolete are expensed. In order to assess the ultimate realization of inventories, the Company is required to make judgments as to future demand requirements compared to current or committed inventory levels. Trade Accounts Receivable Trade accounts receivable represents estimated receivables from customers for revenue recognized related to the Company's tests. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral. Property, Plant and Equipment Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of five four Leases The Company acts as the lessee in its lease agreements, which primarily include operating leases for corporate offices, laboratory space, warehouse space, and certain laboratory and office equipment. The Company determines whether an arrangement is, or contains, a lease at inception and whether the lease should be classified as a finance or operating lease. For all leases, the Company records the present value of lease payments as right-of-use (“ROU”) assets and lease liabilities on the Consolidated Balance Sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations. As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The leases have remaining lease terms of one year to 14 years, some of which include options to extend the lease term for up to 10 years. The Company has taken advantage of certain practical expedients offered to registrants at adoption of Accounting Standards Codification ("ASC") 842, Leases . Lease expense for leases with a term of 12 months or less is recognized on a straight-line basis and is not included in the recognized ROU assets and lease liabilities. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract. Operating leases are included in Operating lease right-of-use assets, Current maturities of operating lease liabilities, and Noncurrent operating lease liabilities in the Consolidated Balance Sheets. Finance leases are included in Other assets, Accrued liabilities, and Other long-term liabilities in the Consolidated Balance Sheets. Intangible Assets Intangible assets are comprised of acquired licenses and technology. Acquired intangible assets are recorded at fair value and amortized over the shorter of the contractual life or the estimated useful life. The Company capitalizes certain costs incurred to develop internal-use software. Implementation and development costs for internal-use software are capitalized as part of Intangible Assets in the Consolidated Balance Sheets. After the implementation of the internal-use software, the capitalized costs are amortized on a straight-line basis over the estimated useful life of the asset. Costs incurred during the post implementation stage of the project are expensed as incurred. As of December 31, 2024 and 2023, the Company had unamortized internal-use software costs of $22.7 million and $11.9 million, respectively. For the years ended December 31, 2024, 2023, and 2022 amortization expense for these capitalized software costs was insignificant. Other Long-Lived Assets The Company continually reviews and monitors long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such indicators are present, the Company performs a recoverability test by comparing the estimated undiscounted future cash flows expected to be generated by the asset or asset group to its carrying amount. If the carrying amount of an asset or asset group exceeds its estimated future undiscounted cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the asset or asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. The Company capitalizes certain implementation costs incurred in cloud computing arrangements and hosting arrangements. The Company's cloud computing arrangements or hosting arrangements are primarily service contracts related to information technology. Implementation and development costs for cloud computing arrangements or hosting arrangements are capitalized as part of Other assets in the Consolidated Balance Sheets. As of December 31, 2024 and 2023, the Company had unamortized cloud computing arrangements or hosting arrangements of $3.4 million and $4.6 million, respectively, within Other assets. For the years ended December 31, 2024, 2023, and 2022, amortization expense for these capitalized amounts was insignificant. Goodwill Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators, and competition. Impairment of goodwill is first assessed using a qualitative approach. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed. The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results. Business Acquisitions/Divestitures The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on third-party valuations that use information and assumptions provided by the Company's management, which consider the Company's estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. To the extent the fair value of the net assets and liabilities acquired exceeds the purchase price, a gain is recognized. In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, Distinguishing Liabilities from Equity , the Company recognizes a liability equal to the fair value of the contingent payments expected to be made as of the acquisition date. This liability is remeasured each reporting period and the changes in the fair value are recognized in General and administrative expenses in the Consolidated Statements of Operations. The Company evaluates its portfolio of businesses on an ongoing basis to ensure alignment with its strategic objectives and to enhance shareholder value. From time to time, the Company may divest certain businesses, product lines, or other non-core assets. Gains or losses from the sale of businesses or assets are included in Goodwill and long-lived asset impairment charges on the Company’s Consolidated Statements of Operations. See Note 16 for further information. Transaction costs associated with acquisitions are expensed as incurred in General and administrative expenses in the Consolidated Statements of Operations. Results of operations and cash flows of acquired companies are included in the operating results from the date of acquisition. Revenue Recognition The Company primarily generates revenue by performing molecular testing, primarily derived from the following categories of products: Hereditary Cancer (MyRisk and BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, Precise Tumor, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). Revenue is recorded at the estimated transaction price. Control is transferred, and revenue is recognized, once test results are released to the healthcare provider and/or patient. The following table presents detail regarding the composition of the Company’s total revenue by product type for the years ended December 31, 2024, 2023, and 2022: Years Ended December 31, (In millions) 2024 2023 2022 Hereditary Cancer $ 364.5 $ 327.8 $ 305.5 Tumor Profiling 125.8 135.6 128.6 Prenatal 177.1 151.3 116.4 Pharmacogenomics 170.2 138.5 127.6 Autoimmune — — 0.3 Total revenue $ 837.6 $ 753.2 $ 678.4 In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue: Years Ended December 31, 2024 2023 2022 (in millions) U.S. RoW Total U.S. RoW Total U.S. RoW Total Hereditary Cancer $ 318.6 $ 45.9 $ 364.5 $ 280.5 $ 47.3 $ 327.8 $ 263.5 $ 42.0 $ 305.5 Tumor Profiling 104.2 21.6 125.8 102.1 33.5 135.6 84.5 44.1 128.6 Prenatal 176.5 0.6 177.1 150.6 0.7 151.3 115.6 0.8 116.4 Pharmacogenomics 170.2 — 170.2 138.5 — 138.5 127.6 — 127.6 Autoimmune — — — — — — 0.3 — 0.3 Total revenue $ 769.5 $ 68.1 $ 837.6 $ 671.7 $ 81.5 $ 753.2 $ 591.5 $ 86.9 $ 678.4 Under ASC 606, Revenue from Contracts with Customers (“ASC 606”), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing tests and releasing the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of the Company’s performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration to be received. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. The estimate of revenue is affected by, among other factors, assumptions for changes in payor mix, payor collections, current customer contractual requirements, experience with collections from third-party payors, and changes in medical policies. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenue in the Consolidated Statements of Operations and Comprehensive Loss. Cash collections for certain tests delivered may differ from rates estimated due to changes in the estimated transaction price for contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, settlements with third-party payors, or as a result of third-party payors disputing our bills or denying payment for tests that we have performed, among other reasons. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. The Company recognized $18.5 million, $7.2 million, and $22.1 million for the years ended December 31, 2024, 2023, and 2022, respectively, for tests in which the performance obligation of delivering the test results was met in prior periods. The changes for all periods presented were primarily driven by changes in the estimated transaction price. Additionally, for the year ended December 31, 2024, the Company recognized $3.0 million in revenue due to a retroactive coverage change by a payor for one of the Company's prenatal products. In accordance with ASC 606, the Company has elected to exclude from the measurement of transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, and certain other taxes. The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. Advertising Costs The Company expenses advertising costs as incurred. The Company incurred advertising costs of $10.3 million, $8.5 million, and $5.3 million for the years ended December 31, 2024, December 31, 2023, and December 31, 2022, respectively. Stock-based Payment Expense We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with ASC 718, Compensation – Stock Compensation ("ASC 718"). Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee’s requisite service period, which is generally the vesting period. Compensation cost for awards with only service conditions are recognized on a straight-line basis over the requisite service period. The fair value of restricted stock units ("RSUs") and performance restricted stock units ("PSUs") that do not have market conditions is based on the number of shares granted and the quoted price of the Company’s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Method. For PSUs, t he Company estimates the likelihood of achievement of the performance conditions at the end of each period. Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Company's Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of the price of the Company's common stock. Income Taxes The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items requires significant judgment and expertise in federal, state, and foreign income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company’s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the Consolidated Financial Statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition, results of operations, or cash flows. Earnings Per Share Basic earnings per share ("EPS") is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. The following is a reconciliation of the denominators of the basic and diluted earnings per share computations: Years Ended December 31, (in millions) 2024 2023 2022 Denominator: Weighted-average shares outstanding used to compute basic EPS 90.6 82.8 80.6 Effect of dilutive stock options and RSUs — — — Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 90.6 82.8 80.6 Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows: Years Ended December 31, (in millions) 2024 2023 2022 Anti-dilutive options and RSUs excluded from EPS computation 6.0 5.1 4.4 Foreign Currency The functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholders’ equity. The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions): Ending balance December 31, 2023 $ (3.7) Period translation adjustments (3.0) Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax 5.9 Ending balance December 31, 2024 $ (0.8) During the years ended December 31, 2024 and 2023, the Company recognized losses related to foreign currency of $1.1 million and $3.4 million, respectively, which is included in Other in the Consolidated Statements of Operations. Recent Accounting Pronouncements Recently Adopted Standards In November 2023, the Financial Accounting Standards Board ("FASB") issued accounting standards update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which enhances the disclosures required for reportable segments in annual and interim consolidated financial statements. ASU 2023-07 is effective for the Company for annual reporting periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the required disclosures effective for the year ended December 31, 2024. The Company has identified consolidated net income (loss) as the measure of segment profitability. The significant expenses presented to the chief operating decision maker ("CODM") are at the same level as presented in Consolidated Statement Operations in these financial statements. Standards Effective in Future Years and Not Yet Adopted In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which requires enhanced income tax disclosures, including disaggregation of information on the rate reconciliation table and disaggregated information related to income taxes paid. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on its income tax disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses , requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.

MARKETABLE INVESTMENT SECURITIE

MARKETABLE INVESTMENT SECURITIES	12 Months Ended
	Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]
MARKETABLE INVESTMENT SECURITIES	MARKETABLE INVESTMENT SECURITIES At December 31, 2024, the Company had no investment securities outstanding. As of December 31, 2023, the Company had no gross unrealized holding gains. The amortized cost, gross unrealized holding losses, and fair value for debt securities classified as available-for-sale securities by major security type and class of security at December 31, 2023 were as follows: (in millions) Amortized Gross Estimated December 31, 2023: Cash and cash equivalents: Cash $ 129.9 $ — $ 129.9 Cash equivalents 2.2 — 2.2 Total cash and cash equivalents 132.1 — 132.1 Available-for-sale: Corporate bonds and notes 8.4 (0.1) 8.3 Municipal bonds 0.5 — 0.5 Total $ 141.0 $ (0.1) $ 140.9 During the years ended December 31, 2023 and 2022, the Company sold $90.4 million and $28.4 million of investments, respectively. The cost of the available for sale security sold was determined using the specific-identification method. The amount of gross realized gains and realized losses upon sales of investments was insignificant for the year ended December 31, 2024 and December 31, 2022. The amount of realized losses upon sales of investments was $1.5 million for the year ended December 31, 2023. As of December 31, 2023, the Company had seven available-for-sale debt securities in a gross unrealized loss position of $0.1 million, with a fair market value of $8.8 million. As of December 31, 2023, the expected losses were determined to be immaterial and as such, the Company did not record an allowance for credit losses. Additional information relating to fair value of marketable investment securities can be found in Note 3.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilized broker quotes in a non-active market for valuation of these securities. Level 3—unobservable inputs. All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. The fair value of the Company’s long-term debt, which it considers a Level 2 measurement, is estimated using a discounted cash flow analysis, based on the Company’s current estimated incremental borrowing rates for similar borrowing arrangements. The fair value of the Company’s long-term debt is estimated to be $40.2 million at December 31, 2024. At December 31, 2024, the Company did not have any financial assets or liabilities requiring fair value re-measurement. The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis as of December 31, 2023: (in millions) Level 1 Level 2 Level 3 Total December 31, 2023 Money market funds (a) $ 2.2 $ — $ — $ 2.2 Corporate bonds and notes — 8.3 — 8.3 Municipal bonds — 0.5 — 0.5 Contingent consideration — — (5.4) (5.4) Total $ 2.2 $ 8.8 $ (5.4) $ 5.6 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest. The following table reconciles the change in the fair value of the contingent consideration during the periods presented: (in millions) Years Ended December 31, 2024 2023 2022 Carrying amount at beginning of period $ 5.4 $ 6.8 $ 8.6 Payment of contingent consideration (5.8) — (3.0) Consideration recognized at acquisition — — 2.1 Change in fair value recognized in the statement of operations 0.4 (1.5) (0.4) Translation adjustments recognized in other comprehensive income (loss) — 0.1 (0.5) Carrying amount at end of period $ — $ 5.4 $ 6.8 For the Level 2 contingent consideration related to the acquisition of Gateway, the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using current financial or operating projections. As of December 31, 2024, the Company has estimated a fair value of $0 related to the Gateway contingent consideration as the achievement of the contingent consideration targets is not considered probable.

PROPERTY, PLANT AND EQUIPMENT,

PROPERTY, PLANT AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	PROPERTY, PLANT AND EQUIPMENT, NET The property, plant and equipment were as follows: December 31, (in millions) 2024 2023 Leasehold improvements $ 78.5 $ 91.3 Equipment 148.5 147.6 Property, plant and equipment, gross 227.0 238.9 Less accumulated depreciation (109.6) (119.9) Property, plant and equipment, net $ 117.4 $ 119.0 During the year ended December 31, 2023, the Company incurred $5.7 million of accelerated depreciation of leasehold improvements and equipment in connection with the Company's decision to cease the use of its previous corporate headquarters in Salt Lake City, Utah and transition corporate support operations to its new facility in west Salt Lake City. The Company formally assigned the previous corporate headquarter lease to a third party as of December 31, 2023. See Note 13 for further discussion. The Company recorded depreciation during the respective periods as follows: Years Ended December 31, (in millions) 2024 2023 2022 Depreciation expense $ 19.5 $ 19.1 $ 11.6

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill The changes in the carrying amount of goodwill for the year ended December 31, 2024 are as follows: (in millions) Year Ended December 31, 2024 Beginning balance $ 287.4 Goodwill impairment (0.8) Translation adjustments (0.3) Ending balance $ 286.3 During the fourth quarter of 2024, UnitedHealthcare announced that it would no longer provide coverage for certain multi-gene panel pharmacogenetic tests, including the Company's GeneSight test, under its commercial, individual exchange, and certain managed Medicaid plans. The change took effect for commercial and individual exchange plans on January 1, 2025, and is expected to take effect for impacted managed Medicaid plans during the first half of 2025. As a result, the Company performed an quantitative impairment test for the goodwill for the Pharmacogenomics reporting unit during the fourth quarter of 2024. The Company also elected to perform a quantitative impairment review of goodwill for its Women's Health and International reporting units. The Company estimated the fair values of each reporting unit using both the market approach, applying an observable multiple of revenue based on guideline public companies, and the income approach, discounting future cash flows based on management's expectations of the current and future operating environments for each reporting unit. The Company corroborated the reasonableness of the estimated reporting unit fair values by reconciling the values to its enterprise value and market capitalization. The goodwill balance at each reporting unit was determined to not be impaired as of December 31, 2024. During the second quarter of 2024, as a result of the disposition of the EndoPredict business, the Company recognized a goodwill impairment charge of $0.8 million for the goodwill allocated to the EndoPredict business within the Company's International reporting unit. The goodwill impairment charge is reflected in Goodwill and long-lived asset impairment charges in the Consolidated Statements of Operations. See Note 17 for further discussion. The Company did not record an impairment of goodwill for the years ended December 31, 2023 and 2022. Intangible Assets The following tables summarize the amounts reported as intangible assets: (in millions) Gross Accumulated Net Weighted-Average Useful Life Weighted-Average Remaining Useful Life At December 31, 2024 Developed technologies $ 560.1 $ (326.5) $ 233.6 10.6 3.6 Internal-use software 1.8 (0.7) 1.1 3.0 1.9 Customer relationships 1.6 (0.3) 1.3 10.0 7.8 Trademarks 6.1 (1.3) 4.8 10.0 7.8 Internal-use software (in-process) 21.6 — 21.6 Total intangible assets $ 591.2 $ (328.8) $ 262.4 (in millions) Gross Accumulated Net Weighted-Average Useful Life Weighted-Average Remaining Useful Life At December 31, 2023 Developed technologies $ 626.1 $ (295.3) $ 330.8 14.4 8.1 Internal-use software 0.8 (0.1) 0.7 3.0 2.5 Customer relationships 1.6 (0.2) 1.4 10.0 8.8 Trademarks 6.1 (0.7) 5.4 10.0 8.8 Internal-use software (in-process) 11.2 — 11.2 Total intangible assets $ 645.8 $ (296.3) $ 349.5 As noted above, UnitedHealthcare announced that it would longer provide coverage for certain multi-gene panel pharmacogenetic tests, including the Company's GeneSight test, which triggered the Company to perform a recoverability test for the Pharmacogenomics asset group during the fourth quarter of 2024. The Company performed the recoverability test by comparing the carrying value of the asset group to its estimated undiscounted future cash flows. The analysis indicated that the carrying value exceeded the recoverable amount, requiring the Company to determine the fair value of the asset group. The fair value of the developed technology was determined using a discounted cash flow model. The primary assumptions used in the discounted cash flow model included projected revenue and profitability associated with the developed technology based on management's forecast and a discount rate reflective of the risk-adjusted cost of capital of 10%. As the carrying value for the developed technology asset exceeded the relative fair value, the Company recognized an impairment charge of $43.0 million during the year ended December 31, 2024, which is included in " Goodwill and long-lived asset impairment charges The Company determined there was no impairment of long-lived intangible assets for the years ended December 31, 2023 and 2022. In recent years, the Company has invested in the development of internal-use software. As of December 31, 2024, the Company has capitalized $21.6 million related to projects under development. The Company expects the majority of the current in-process internal-use software projects to be completed in fiscal year 2025. As of December 31, 2024, the Company's developed technologies have estimated remaining useful lives ranging between 5 and 12 years. The Company's acquired trademarks and customer relationships have an estimated remaining useful life of approximately 8 years as of December 31, 2024. The Company's internal-use software assets are amortized over the estimated useful life of the software, which is generally 3 years. The Company recorded amortization during the respective periods for intangible assets as follows: Years Ended December 31, (in millions) 2024 2023 2022 Amortization of intangible assets $ 42.1 $ 42.8 $ 41.1 Future amortization expense of intangible assets as of December 31, 2024 is estimated to be as follows (in millions): Years Ended December 31, Amortization Expense 2025 $ 37.4 2026 37.2 2027 36.8 2028 36.7 2029 36.7 Thereafter 77.6 Total $ 262.4

ACCRUED LIABILITIES

ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
ACCRUED LIABILITIES	ACCRUED Accrued liabilities consist of the following: December 31, (in millions) 2024 2023 Employee compensation and benefits $ 57.4 $ 49.7 Accrued taxes payable 5.1 4.6 Refunds payable and reserves 19.9 20.1 Short-term contingent consideration — 3.1 Accrued royalties 6.5 5.3 Legal settlement 2.8 6.0 Lease termination accrual 3.8 4.4 Escrow liability 7.5 — Other accrued liabilities 16.0 20.7 Total accrued liabilities $ 119.0 $ 113.9 Revenue is constrained in anticipation of requests for refunds of payments made previously by insurance carriers. The following table summarizes the balance and activity of the refunds payable and reserves for the years ended December 31, 2024 and 2023: Years Ended December 31, (in millions) 2024 2023 Beginning balance $ 20.1 $ 19.3 Recoupments paid (11.3) (13.8) Additions to the reserve 11.1 14.6 Ending balance $ 19.9 $ 20.1

LONG-TERM DEBT

LONG-TERM DEBT	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
LONG-TERM DEBT	LONG-TERM DEBT On June 30, 2023, the Company entered into an asset-based revolving credit facility (the “ABL Facility”) with an initial maximum principal amount of $90.0 million, with JPMorgan Chase Bank, N.A., as administrative agent and issuing bank, the other lender parties thereto, and certain of the Company's domestic subsidiaries (the "Guarantors"). On October 31, 2023, the Company entered into an amendment to the ABL Facility to increase the maximum principal amount of the available revolving line of credit by $25.0 million for a total maximum principal commitment of $115.0 million under the ABL Facility, which was effected through a new commitment provided by a new lender, Goldman Sachs Bank USA. The ABL Facility matures on June 30, 2026. The obligations of the Company are guaranteed by the Guarantors and the ABL Facility is secured by substantially all of the assets of the Company and the Guarantors. The Company had long-term debt of $39.6 million and $38.5 million under the ABL Facility at December 31, 2024 and December 31, 2023, respectively, net of $0.9 million and $1.5 million of debt issuance costs, respectively. Proceeds from the ABL Facility were or will be used for the working capital needs and general corporate purposes of the Company and its subsidiaries. Availability under the ABL Facility is subject to a borrowing base, which is the lesser of (a) 85% of the Company's and the Guarantors' eligible accounts receivable plus certain cash held in a segregated and fully-blocked account with the administrative agent in an amount up to $20.0 million ("Eligible Cash") minus any reserves established by the administrative agent in accordance with the ABL Facility, and (b) the aggregate amount of cash collections from eligible accounts of the Company and the Guarantors for the 60 consecutive days most recently ended. Subject to certain conditions, the Company can freely withdraw cash from the Eligible Cash account, provided that any reduction in the Eligible Cash amount will have a corresponding reduction in the borrowing base under the ABL Facility. Loans outstanding under the ABL Facility will bear interest at a rate per annum equal to, at the option of the Company, either (a) the greatest of (i) the daily Prime Rate, (ii) the daily NYFRB Rate plus 0.5%, and (iii) the monthly Adjusted Term SOFR Rate (as defined below) plus 1.0% (the “ABR”) plus an applicable margin ranging from 1.0% to 1.5% depending on the aggregate average unused availability under the ABL Facility during the prior quarter or (b) term Secured Overnight Financing Rate ("SOFR") for a tenor of one, three or six months (at the Company’s election) plus 0.1% (the “Adjusted Term SOFR Rate”) plus an applicable margin ranging from 2.0% to 2.5% depending on the average unused availability under the ABL Facility during the prior quarter, with an ABR floor of 1.0% and an Adjusted Term SOFR Rate floor of 0.0%. Under the ABL Facility, the undrawn fee ranges from 37.5 to 50 basis points based on the daily amount of the available revolving commitment. The weighted average interest rate for borrowings under the ABL Facility as of December 31, 2024 was 7.8%. The interest rate for borrowings under the ABL Facility as of December 31, 2023 was 9.75%. The Company may elect to prepay all or any portion of the amounts owed prior to the maturity date without premium or penalty. The ABL Facility is also subject to customary mandatory prepayments with the proceeds of unpermitted indebtedness and upon the occurrence of an over-advance. Voluntary and mandatory prepayments and all other payments of the ABL Facility must be accompanied by payment of accrued interest on the principal amount repaid or prepaid. The ABL Facility contains customary loan terms, interest rates, representations and warranties and affirmative and negative covenants, in each case, subject to customary limitations, exceptions, and exclusions. Covenants under the ABL Facility limit or restrict the Company and its subsidiaries' ability to incur liens, incur indebtedness, dispose of assets, make investments, make certain restricted payments (including dividends), merge or consolidate, and enter into certain speculative hedging arrangements. The ABL Facility requires the Company and the Guarantors, on a consolidated basis, to maintain a fixed charge coverage ratio of at least 1.0 to 1.0 if availability under the ABL Facility is less than the greater of (a) $10.6 million and (b) 12.5% of the lesser of the maximum commitment amount and the borrowing base. As of December 31, 2024, availability under the ABL Facility was $56.0 million. For the years ended December 31, 2024 and December 31, 2023, the Company was compliant with all such financial covenants. In addition, the ABL Facility includes a number of customary events of default. If any event of default occurs (subject, in certain instances, to specified grace periods), the principal, premium, if any, interest, and any other monetary obligations on all the then-outstanding amounts under the ABL Facility may become due and payable immediately. Under the terms of the ABL Facility, if (i) an event of default has occurred and is continuing or (ii) availability under the ABL Facility is less than the greater of (a) $12.5 million and (b) 15% of the lesser of the maximum commitment amount and the borrowing base, the Company will become subject to cash dominion, upon which the administrative agent will apply funds credited to a collection account to first prepay any outstanding protective advances, second to prepay any revolving loans and third, to cash collateralize any outstanding letter of credit exposure. Such cash dominion period will end when availability has remained in excess of the greater of (i) $12.5 million and (ii) 15% of the lesser of the maximum commitment amount and the borrowing base for a period of 45 consecutive days and no event of default is continuing.

OTHER LONG-TERM LIABILITIES

OTHER LONG-TERM LIABILITIES	12 Months Ended
	Dec. 31, 2024
Other Liabilities Disclosure [Abstract]
OTHER LONG-TERM LIABILITIES	OTHER LONG-TERM LIABILITIES The Company's other long-term liabilities were as follows: December 31, (in millions) 2024 2023 Contingent consideration $ — $ 2.3 Escrow liability — 7.5 Legal settlements — 24.0 Other 2.2 7.5 Total other long-term liabilities $ 2.2 $ 41.3

PREFERRED AND COMMON STOCKHOLDE

PREFERRED AND COMMON STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
PREFERRED AND COMMON STOCKHOLDERS' EQUITY	PREFERRED AND COMMON STOCKHOLDERS' EQUITY The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no shares of preferred stock outstanding at December 31, 2024 and December 31, 2023. The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. In November 2023, the Company completed an underwritten public offering in which it sold 7.4 million shares of its common stock at a price of $17.00 per share, for gross proceeds of $126.5 million and net proceeds of $117.6 million. There were 91.3 million and 89.9 million shares of common stock issued and outstanding at December 31, 2024 and 2023, respectively. Shares of common stock issued and outstanding Years Ended December 31, (in millions) 2024 2023 2022 Beginning common stock issued and outstanding 89.9 81.2 80.0 Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans 1.4 1.3 1.2 Common stock issued for public offering — 7.4 — Common stock issued and outstanding at end of period 91.3 89.9 81.2

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION On November 30, 2017, the Company’s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee (the "CHCC") of the Board of Directors, to make grants of restricted and unrestricted stock and stock unit awards to employees, consultants and directors. Stockholders have subsequently approved amendments to the 2017 Plan increasing the shares available to grant thereunder, including most recently at the Company's annual meeting of stockholders held on June 1, 2023, when stockholders approved an amendment to the 2017 Plan to increase the aggregate number of shares of common stock available thereunder for the granting of awards by an additional 4.8 million shares. As of December 31, 2024, the Company had 2.2 million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. The number of shares, terms, and vesting periods are generally determined by the Company’s Board of Directors or the CHCC on an award-by-award basis. RSUs granted to employees generally vest either ratably over three The performance and market conditions associated with PSU awards granted during the year ended December 31, 2024 include vesting that is based on revenue targets (34% weighting), adjusted earnings per share targets (33% weighting), and relative total stockholder return (33% weighting) measured against the Nasdaq Health Care Index (IXHC) using the 20-trading day averages at the beginning and end of the measurement period. The measurement period for the relative total stockholder return metric is January 1, 2024 through December 31, 2026, and the revenue and adjusted earnings per share metrics will be measured based on fiscal year 2026 results. The Company estimates the likelihood of achievement of performance conditions for all PSU awards at the end of each period. To the extent those awards or portions thereof are considered probable of being achieved, such awards or portions thereof are expensed over the performance period. The portion of the awards pertaining to relative total stockholder return represent market conditions and, accordingly, the estimated fair value of such awards is recognized over the performance period. Stock Options A summary of the stock option activity under the Company's inducement awards for the twelve months ended December 31, 2024 is as follows: (number of shares in millions) Number Weighted Weighted Options outstanding at December 31, 2023 0.7 $ 13.38 Options outstanding at December 31, 2024 0.7 13.38 2.62 Options exercisable at December 31, 2024 0.5 13.38 2.62 Options vested and expected to vest 0.2 $ 13.38 2.62 There were no options granted during the years ended December 31, 2024, 2023, and 2022. Restricted Stock Units A summary of the RSU awards activity under the Company's equity plans and inducement awards, including PSU awards, for the year ended December 31, 2024 is as follows: (number of shares in millions) Number Weighted RSUs unvested and outstanding at December 31, 2023 4.4 $ 24.37 RSUs granted 2.7 $ 22.09 Less: RSUs vested (1.6) $ 22.98 RSUs canceled (0.2) $ 23.58 RSUs unvested and outstanding at December 31, 2024 5.3 $ 23.66 The weighted average grant-date fair value of RSUs granted during the years ended December 31, 2024, 2023, and 2022, was $22.09, $23.02, and $25.78, respectively. The fair value of RSUs that vested during the years ended December 31, 2024, 2023, and 2022, was $37.9 million, $30.5 million, and $31.0 million, respectively. Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows: Years Ended December 31, (in millions) 2024 2023 2022 Cost of revenue $ 1.6 $ 1.4 $ 1.7 Research and development expense 8.8 4.0 5.2 Sales and marketing expense 9.0 7.2 6.2 General and administrative expense 30.4 28.1 25.0 Total stock-based compensation expense $ 49.8 $ 40.7 $ 38.1 As of December 31, 2024, there was $70.9 million of total unrecognized stock-based compensation expense that will be recognized over a weighted-average period of 2.0 years. The Company recognizes forfeitures as they occur. The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows: (in millions) December 31, 2024 Aggregate intrinsic value of options outstanding $ 0.2 Aggregate intrinsic value of options fully vested 0.2 Aggregate intrinsic value of RSUs outstanding 71.7 Employee Stock Purchase Plan The Company also has an Employee Stock Purchase Plan that was initially approved by stockholders in 2012 and was amended and approved by the Board of Directors of the Company on September 23, 2021 and the stockholders on June 2, 2022 (the “Amended and Restated 2012 Purchase Plan”), under which 4.0 million shares of common stock were authorized for issuance. Shares are issued under the Amended and Restated 2012 Purchase Plan twice yearly at the end of each offering period and the number of shares that may be purchased by any participant during an offering period is limited to 5,000 shares. The first offering period of 2024 started on December 1, 2023 and ended on May 31, 2024. The second offering period of 2024 began on June 1, 2024 and ended on November 30, 2024. As of December 31, 2024, 0.9 million shares of common stock were available for issuance under the Amended and Restated 2012 Purchase Plan. Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the periods reported are as follows: Years Ended December 31, (in millions) 2024 2023 2022 Shares purchased under the plan 0.4 0.4 0.3 Plan compensation expense $ 2.1 $ 2.2 $ 1.9 The fair value of shares issued under the Amended and Restated 2012 Purchase Plan that was in effect for each period reported was calculated using the Black‑Scholes option-pricing model using the weighted-average assumptions below. Each of these inputs is subjective and its determination generally requires significant judgment. Years Ended December 31, 2024 2023 2022 Risk-free interest rate 5.3% 5.1% 1.4% Expected dividend yield —% —% —% Expected life (in years) 0.5 0.5 0.5 Expected volatility 50% 56% 53%

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Income tax expense (benefit) consists of the following: Years Ended December 31, (in millions) 2024 2023 2022 Current: Federal $ 3.4 $ 3.4 $ (0.5) State 1.5 1.8 1.9 Foreign 1.2 0.2 0.5 Total current 6.1 5.4 1.9 Deferred: Federal (15.5) (51.8) (25.8) State (5.5) (5.2) (4.8) Foreign 3.1 0.1 (2.9) Change in valuation allowance 15.6 52.6 3.0 Total deferred (2.3) (4.3) (30.5) Total income tax expense (benefit) $ 3.8 $ 1.1 $ (28.6) Loss before income taxes consists of the following: Years Ended December 31, (in millions) 2024 2023 2022 United States $ (125.4) $ (263.2) $ (141.3) Foreign 1.9 1.0 0.7 Total $ (123.5) $ (262.2) $ (140.6) The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows: Years Ended December 31, (in millions) 2024 2023 2022 Federal income tax benefit at the statutory rate $ (25.9) 21.0 % $ (54.9) 21.0 % $ (29.5) 21.0 % State income taxes, net of federal benefit (2.4) 1.9 % (4.1) 1.6 % (3.3) 2.3 % Research and development credits (0.4) 0.3 % (1.6) 0.6 % (3.5) 2.5 % Uncertain tax positions 2.8 (2.3) % 3.7 (1.4) % 0.6 (0.4) % Stock-based incentive awards 0.8 (0.6) % 1.2 (0.5) % 2.5 (1.8) % Foreign rate differential 3.3 (2.7) % (0.4) 0.2 % — — % Change in valuation allowance 15.7 (12.7) % 52.6 (20.1) % 2.6 (1.8) % Non-deductible officer compensation 3.9 (3.2) % 3.0 (1.1) % 3.5 (2.5) % Acquisitions and dispositions 5.1 (4.1) % 0.1 — % (0.1) 0.1 % Other, net 0.9 (0.7) % 1.5 (0.7) % (1.4) 0.9 % Total income tax expense (benefit) $ 3.8 (3.1) % $ 1.1 (0.4) % $ (28.6) 20.3 % The significant components of the Company’s deferred tax assets and liabilities were comprised of the following: December 31, (in millions) 2024 2023 Deferred tax assets: Net operating loss carryforwards $ 62.7 $ 77.1 Stock compensation expense 6.6 5.0 Research and development credits 20.6 20.8 Lease liability 24.4 28.0 Capitalized research and development costs 54.3 38.4 Accrued expenses and liabilities 16.5 22.5 Other, net — 3.2 Total gross deferred tax assets 185.1 195.0 Less valuation allowance (111.9) (95.0) Total deferred tax assets 73.2 100.0 Deferred tax liabilities: Intangible assets 55.5 84.2 Lease right-of-use assets 13.3 15.5 Property, plant and equipment 3.2 1.9 Other, net 0.8 — Total deferred tax liabilities 72.8 101.6 Net deferred tax asset (liability) $ 0.4 $ (1.6) The Company incurred a loss in the current year and the two preceding years, resulting in a three-year cumulative loss. Pursuant to ASC 740, Income Taxes ("ASC 740"), a company that is in a cumulative loss position must consider the weight of this significant negative evidence together with the weight of other positive and negative evidence that is available to determine the realizability of deferred tax assets and that overcoming negative evidence such as cumulative losses in recent years is difficult. Due to significant negative evidence and the lack of sufficient positive evidence, the Company has applied a valuation allowance to the majority of its deferred tax assets, leaving a remaining deferred tax asset balance of $0.4 million. For those foreign entities for which an election has been made to be treated as disregarded for U.S. tax purposes, the appropriate U.S. jurisdiction deferred tax assets and liabilities have been recorded. At December 31, 2024, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated: Carryforwards (in millions) Amount Subject to Sections 382, 383 Expires Through Federal net operating loss $ 32.2 Yes 2033 Indefinite Federal capital loss 13.8 No 2026 2029 Utah net operating loss 0.9 No Indefinite Indefinite California net operating loss 5.0 Yes 2029 2044 Other state net operating loss 6.3 Yes Various Various Foreign net operating losses (various jurisdictions) 4.3 No Various Various Federal research credit 10.5 Yes 2027 2044 Utah research credit 4.9 No 2024 2038 California research credit 5.2 No Indefinite Indefinite The Company provides for uncertain tax positions when such tax positions do not meet the recognition thresholds or measurement criteria as set forth in ASC 740. As of December 31, 2024, the Company had net unrecognized tax benefits of $51.7 million. The Company’s gross unrecognized tax benefits as of the years ended December 31, 2024, 2023, and 2022, and the changes in those balances are as follows: Years Ended December 31, (in millions) 2024 2023 2022 Unrecognized tax benefits at the beginning of period $ 48.1 $ 43.9 $ 32.1 Gross increases - current year tax positions 1.0 0.8 12.9 Gross increases - prior year tax positions 2.6 3.6 1.6 Gross decreases - prior year tax positions — (0.2) (2.0) Gross decreases - settlements — — (0.7) Unrecognized tax benefits at end of year $ 51.7 $ 48.1 $ 43.9 Interest and penalties in year-end balance $ 8.8 $ 6.4 $ 4.1 In 2022, the Company filed a U.S. federal tax return taking an uncertain tax position that was not recorded as a benefit or deferred tax asset in the financial statements but for which a $12.0 million unrecognized tax benefit has been included in the table above. The Company believes it is reasonably possible that a decrease of up to $48 million in unrecognized tax benefits may be necessary within the coming year. Interest and penalties related to uncertain tax positions are included as a component of Income tax expense (benefit) and all other interest and penalties are included as a component of Other income (expense) in the Consolidated Statements of Operations. For the years ended December 31, 2024 and December 31, 2023, $32.7 million and $30.2 million of the unrecognized tax benefits, if recognized, would affect the effective tax rate, respectively. The Company files U.S. federal, foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company is currently under audit by the state of California for years ended June 30, 2017 through June 30, 2018. Annual tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES The Company is involved from time to time in various disputes, claims, and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amounts of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding its business which may result in adverse judgments, settlements, fines, penalties, injunctions, or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company has received subpoenas from time to time related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations, or other laws. The Company intends to defend its current litigation matters but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows. The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual and disclosure in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the proceedings may be in early stages, there may be uncertainty as to the outcome of pending appeals or motions, there may be significant factual issues to be resolved, and there may be complex or novel legal theories to be presented. In addition, damages may not be specified or the damage amounts claimed may be unsupported, exaggerated or unrelated to possible outcomes, and therefore, such amounts are not a reliable indicator of potential liability. As of December 31, 2024, the Company has not recorded any material accrual for loss contingencies associated with legal proceedings or other matters or determined that an unfavorable outcome is probable and reasonably estimable in accordance with ASC 450, Contingencies . However, it is possible that the ultimate resolution of legal proceedings or other matters, if unfavorable, may be material to the Company's results of operations, financial condition or cash flows. Further, in the event that damages from an unfavorable resolution of one or more of these proceedings exceed the aggregate amount of the coverage limits of the Company’s insurance, or if the Company’s insurance carriers disclaim coverage, the amounts payable by the Company could also have a material adverse impact on the Company’s results of operations, financial condition or cash flows. From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments. Qui Tam Lawsuit

LEASES

LEASES	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
LEASES	LEASES The Company leases certain office spaces, research and development laboratory facilities, and office equipment with remaining lease terms ranging from approximately one The Company has continued to execute on its multi-year strategy to reset its real estate footprint. During the year ended December 31, 2024, the Company took full possession of the remaining phases of its west Salt Lake City, Utah facility. The Company has completed the transition of its corporate support operations and certain laboratory operations from its legacy facilities in Salt Lake City to its new facility in west Salt Lake City. The Company plans to complete the transition of its remaining laboratory facilities to its next generation laboratory facilities in early 2025. Additionally, during 2024, the Company amended the lease for its west Salt Lake City facility to include approximately 63,000 additional square feet of laboratory space in anticipation of future operating needs. The lease has a term of 12 years and ends coterminous with the rest of the lease. The amendment is expected to commence in fiscal year 2026 with future rent payments totaling $18.2 million. During the year ended December 31, 2023, the Company assigned the lease for its previous corporate headquarters to a third party. As a result, the operating ROU asset and operating lease liability associated with the lease was removed from the Company's Condensed Consolidated Balance Sheets. As of December 31, 2024, the Company has accrued $3.8 million for the remaining future payments under the lease assignment agreement, which was included in Accrued liabilities in the Consolidated Balance Sheets. Also during the year ended December 31, 2023, the Company modified the remaining lease term of certain other Salt Lake City, Utah facilities reducing the associated ROU asset and lease liability by $6.4 million. The Company performed evaluations of its contracts and determined the majority of its identified leases are operating leases. For the year ended December 31, 2024, the Company incurred $21.0 million in operating lease costs which are included in Operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $5.0 million was variable lease expense, which was not included in the measurement of the Company's operating ROU assets and lease liabilities. The variable rent expense is comprised primarily of the Company's proportionate share of operating expenses, property taxes, and insurance and is classified as lease expense due to the Company's election to not separate lease and non-lease components. For the year ended December 31, 2023, the Company incurred $25.9 million in lease costs which are included in Operating expenses in the Consolidated Statements of Operations in relation to these operating leases. Of such lease costs, $3.5 million was variable lease expense, which was not included in the measurement of the Company's operating ROU assets and lease liabilities. The Company's finance leases are immaterial. As of December 31, 2024, the maturities of the Company’s operating lease liabilities were as follows: Year Ended (in millions) : 2025 $ 18.9 2026 12.3 2027 12.3 2028 12.4 2029 12.1 Thereafter 73.7 Total future lease payments 141.7 Less: amounts representing interest 41.0 Present value of future lease payments 100.7 Less: current maturities of operating lease liabilities (12.8) Noncurrent operating lease liabilities $ 87.9 As of December 31, 2024, the weighted average remaining lease term is 9.3 years and the weighted average discount rate used to determine the operating lease liability was 6.5%. As the implicit rate in the Company's leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. When calculating the Company’s incremental borrowing rates, the Company gives consideration to its credit risk, term of the lease, total lease payments and adjusts for the impacts of collateral, as necessary. The lease term used may reflect any option to extend or terminate the lease when it is reasonably certain the Company will exercise such options. Lease expenses for the Company's operating leases are recognized on a straight-line basis over the lease term.

EMPLOYEE DEFERRED SAVINGS PLAN

EMPLOYEE DEFERRED SAVINGS PLAN	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
EMPLOYEE DEFERRED SAVINGS PLAN	EMPLOYEE DEFERRED SAVINGS PLAN The Company has a deferred savings plan which qualifies under Section 401(k) of the Internal Revenue Code. Substantially all of the Company’s U.S. employees are covered by the plan. The Company makes matching contributions of 50.0% of each employee’s contribution with the employer’s contribution not to exceed 4.0% of the employee’s compensation. The Company’s recorded contributions to the plan are as follows: Years Ended December 31, (in millions) 2024 2023 2022 Deferred savings plan contributions $ 10.3 $ 10.0 $ 9.0

SEGMENT AND RELATED INFORMATION

SEGMENT AND RELATED INFORMATION	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
SEGMENT AND RELATED INFORMATION	SEGMENT AND RELATED INFORMATION The Company’s business is aligned with how the CODM reviews performance and makes decisions in managing the Company. The Company has identified the President and Chief Executive Officer as the CODM. The CODM regularly reviews consolidated financial information for the purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. Accordingly, the Company has determined that it operates as a single operating segment. The Company has identified consolidated net income (loss) as the measure of segment profitability. The significant expenses and other segment expenses presented to the CODM are at the same level as presented in Consolidated Statement Operations in these financial statements. The Company's long-lived assets by geographical region are as follows: December 31, (in millions) 2024 2023 Long-lived assets: United States $ 728.1 $ 794.6 Rest of world 1.4 38.3 Total $ 729.5 $ 832.9

BUSINESS ACQUISITION

BUSINESS ACQUISITION	12 Months Ended
	Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
BUSINESS ACQUISITION	BUSINESS ACQUISITIONOn February 1, 2024, the Company acquired from Intermountain Health select assets for an immaterial amount from its Intermountain Precision Genomics ("IPG") laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah (the "Precise acquisition"). In connection with the Precise acquisition, the Company recognized a gain of $2.2 million, which is included in Other income in the Consolidated Statements of Operations.

DIVESTITURE

DIVESTITURE	12 Months Ended
	Dec. 31, 2024
Discontinued Operations and Disposal Groups [Abstract]
DIVESTITURE	DIVESTITURE On August 1, 2024, the Company completed the sale of its EndoPredict business to Eurobio Scientific ("Eurobio") for net cash consideration of $10.0 million, subject to customary closing adjustments. The transaction was accounted for as a sale of business. The Company recognized a total net loss, including transaction expenses, of $12.4 million during the twelve months ended December 31, 2024 in connection with this sale. The loss is included in Goodwill and long-lived asset impairment charges on the Consolidated Statements of Operations. The recognized loss included the release of $4.4 million of foreign currency translation adjustments previously included in Accumulated other comprehensive income (loss). As part of the transaction, the Company licensed the rights from Eurobio to continue to sell EndoPredict as a laboratory developed test outside of the European Union and licensed to Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	12 Months Ended
	Dec. 31, 2024
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION The Company's supplemental cash flow information for the respective periods are as follows: December 31, (in millions) 2024 2023 2022 Cash paid for income taxes $ 2.7 $ 1.9 $ 1.8 Cash paid for interest 1.9 1.4 — Non-cash investing and financing activities: Change in operating lease right-of-use assets and lease liabilities Operating lease right-of-use assets $ 3.1 $ (31.0) $ 46.9 Operating lease liabilities (3.1) 36.7 (46.9) Tenant improvement allowance not yet received — — 22.9 Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities 6.4 6.9 10.0

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Pay vs Performance Disclosure
Net loss	$ (127.3)	$ (263.3)	$ (112)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	12 Months Ended
	Dec. 31, 2024 shares	Dec. 31, 2024 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Dale Muzzey [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		On December 12, 2024, Dale Muzzey, the Company's Chief Scientific Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 22,906 shares of common stock. The plan expires on the earlier of (i) the date all of the shares under the plan have been sold and (ii) December 31, 2025.
Name	Dale Muzzey
Title	Chief Scientific Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	December 12, 2024
Expiration Date	December 31, 2025
Arrangement Duration	384 days
Aggregate Available	22,906	22,906

Insider Trading Policies and Pr

Insider Trading Policies and Procedures	12 Months Ended
	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true

Cybersecurity Risk Management a

Cybersecurity Risk Management and Strategy Disclosure	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	We recognize the critical importance of maintaining the trust and confidence of patients, business partners, payors, clinical trial participants, and employees toward our business and are committed to protecting the confidentiality, integrity and availability of our business operations and systems. Our Board of Directors is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security, and availability of the information that we collect and store by identifying, preventing, and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur. We generally follow the HITRUST Common Security Framework in our cybersecurity policies, standards, processes, and practices. To identify and assess material risks from cybersecurity threats, we maintain a cybersecurity risk management program that includes the identification, prioritization, and management of technical and non-technical risk to the confidentiality, integrity, or availability of patient, employee, clinical trial participant, payor, business partner, and company information. This program considers the risks associated with our industry and the technical and regulatory requirements related to the information systems and data involved. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process. We have developed policies, standards, processes, and practices designed to protect our information systems and data from unauthorized access, cybersecurity attacks, and other security incidents. The policies, standards, processes, and practices are implemented and enforced by dedicated IT and cybersecurity professionals. We utilize a variety of control measures and cybersecurity technologies that are designed to protect our availability of critical information systems and data, maintain regulatory compliance, assess, identify, and manage our material risks from cybersecurity threats, and protect against and respond to security incidents. These controls and processes are reviewed periodically and include the following activities: • we monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws; • through our policies, practices, and contracts, as applicable, we require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care; • we utilize technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, virtual private networks (VPN), Web Application Firewalls (WAF), intrusion detection systems, antivirus and endpoint detection and response software, multi-factor authentication (MFA), data encryption, encrypted backups, vulnerability scanning and patching, email anti-phishing technology, malicious URL and IP filtering, application controls, USB control and threat intelligence services; • our cybersecurity personnel include certified security professionals who are experienced in networks, computer systems, cloud cybersecurity, cybersecurity risk management, incident response, and security awareness training; • we regularly test and monitor our cybersecurity defenses to ensure that they are effective; and • we also conduct security awareness training for all employees to help them identify and mitigate cybersecurity risks. We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, under the risk factor “ Security breaches, loss of data and other disruptions, including from cyberattacks and other cybersecurity incidents, could compromise personal, confidential, or other sensitive or proprietary information related to our business, prevent us from accessing critical information or expose us to liability, which could adversely affect our business and our reputation ”, included in Part I, Item 1A of this Annual Report on Form 10-K, which disclosures are incorporated by reference into this Item 1C. We did not experience any material cybersecurity incidents during the last fiscal year. We have an incident response plan and processes in place for responding to cybersecurity incidents. The process includes steps to identify, contain, investigate, and remediate the impacts of the incident, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation. The plan involves the participation of a security incident response team that includes our Chief Legal Officer, our Privacy Officer, and other senior leaders in finance, communication, human resources, and legal. The plan includes procedures to communicate the incident to management and customers as appropriate and to provide information as required to state and federal law enforcement and regulatory bodies.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	In general, we seek to address cybersecurity risks through a comprehensive, cross-functional approach that is focused on preserving the confidentiality, security, and availability of the information that we collect and store by identifying, preventing, and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur. We generally follow the HITRUST Common Security Framework in our cybersecurity policies, standards, processes, and practices. To identify and assess material risks from cybersecurity threats, we maintain a cybersecurity risk management program that includes the identification, prioritization, and management of technical and non-technical risk to the confidentiality, integrity, or availability of patient, employee, clinical trial participant, payor, business partner, and company information. This program considers the risks associated with our industry and the technical and regulatory requirements related to the information systems and data involved. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Cybersecurity is an important part of our risk management processes and an area of focus for our Board of Directors and management. In general, our Audit and Finance Committee of our Board of Directors has primary responsibility for and oversight over cybersecurity threats and our information security management program and considers specific risks, including, for example, risk associated with our strategic plan and business operations. The Audit and Finance Committee receives regular reports from our Chief Technology Officer and Senior Vice President, Technology - Enterprise IT and Engineering, on, among other things, material cybersecurity threat risks or incidents and developments, assessments of our security program and overall security posture, our incident response plan, and initiatives to strengthen our information security systems and mitigate cybersecurity risks. The Audit and Finance Committee, including Rashmi Kumar, provides insights and guidance to management on cybersecurity related matters. Ms. Kumar, who currently serves as Senior Vice President, Chief Information Officer, of Medtronic plc, is a seasoned technology leader with extensive experience in cybersecurity and information technology matters. Management, along with the chair of the Audit and Finance Committee and Ms. Kumar, regularly report to the Board of Directors on cybersecurity risks and other related matters reviewed by the Audit and Finance Committee.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Chief Technology Officer, who is supported by our leaders in Information Technology, Information Security, and IT Security Compliance.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Chief Technology Officer, who is supported by our leaders in Information Technology, Information Security, and IT Security Compliance. These management team members are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, our Chief Technology Officer and Senior Vice President, Technology - Enterprise IT and Engineering regularly report to our Audit and Finance Committee about cybersecurity threat risks, among other cybersecurity related matters.
Cybersecurity Risk Role of Management [Text Block]	Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Chief Technology Officer, who is supported by our leaders in Information Technology, Information Security, and IT Security Compliance. These management team members are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, our Chief Technology Officer and Senior Vice President, Technology - Enterprise IT and Engineering regularly report to our Audit and Finance Committee about cybersecurity threat risks, among other cybersecurity related matters.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, are led by our Chief Technology Officer, who is supported by our leaders in Information Technology, Information Security, and IT Security Compliance. These management team members are informed about and monitor the prevention, mitigation, detection, and remediation of cybersecurity incidents through their management of, and participation in, the cybersecurity risk management and strategy processes described above, including the operation of our incident response plan. As discussed above, our Chief Technology Officer and Senior Vice President, Technology - Enterprise IT and Engineering regularly report to our Audit and Finance Committee about cybersecurity threat risks, among other cybersecurity related matters.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	The Audit and Finance Committee receives regular reports from our Chief Technology Officer and Senior Vice President, Technology - Enterprise IT and Engineering, on, among other things, material cybersecurity threat risks or incidents and developments, assessments of our security program and overall security posture, our incident response plan, and initiatives to strengthen our information security systems and mitigate cybersecurity risks. The Audit and Finance Committee, including Rashmi Kumar, provides insights and guidance to management on cybersecurity related matters. Ms. Kumar, who currently serves as Senior Vice President, Chief Information Officer, of Medtronic plc, is a seasoned technology leader with extensive experience in cybersecurity and information technology matters. Management, along with the chair of the Audit and Finance Committee and Ms. Kumar, regularly report to the Board of Directors on cybersecurity risks and other related matters reviewed by the Audit and Finance Committee.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The Audit and Finance Committee receives regular reports from our Chief Technology Officer and Senior Vice President, Technology - Enterprise IT and Engineering, on, among other things, material cybersecurity threat risks or incidents and developments, assessments of our security program and overall security posture, our incident response plan, and initiatives to strengthen our information security systems and mitigate cybersecurity risks.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Basis of Financial Statement Presentation	Basis of Financial Statement Presentation Myriad Genetics, Inc. (together with its subsidiaries, the "Company" or "Myriad") is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower health care costs. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. The Company’s principal executive office is located in Salt Lake City, Utah.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates and assumptions include revenue recognition estimates for the average expected reimbursement per test, valuation allowances for deferred income tax assets, our incremental borrowing rates used to calculate our lease balances, stock-based compensation, purchase accounting, and impairment analysis of goodwill and long-lived assets. Actual results could differ from those estimates.
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the total assets, total liabilities, stockholders' equity, or cash flows from operations.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company limits its exposure to loss by placing its cash in financial institutions with high credit ratings. The Company's cash consists of deposits held with banks that generally exceed federally insured limits of $250,000 per customer. Substantially all of the Company’s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related health care programs are funded by the U.S. and state governments. The Company does not require collateral from its customers.
Cash and Cash Equivalents	Cash and Cash Equivalents
Restricted Cash	Restricted Cash
Marketable Investment Securities	Marketable Investment Securities The Company has classified its marketable investment securities, all of which are debt securities, as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in Accumulated other comprehensive loss in Stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The Company’s cash equivalents consist of short-term, highly liquid investments that are readily convertible to known amounts of cash. A decline in the market value of any available-for-sale security below cost that is deemed other than temporary results in a charge to earnings and establishes a new cost basis for the security. Losses are charged against Other income (expense) when a decline in fair value is determined to be other than temporary. The Company reviews several factors to determine whether a loss is other than temporary. These factors include but are not limited to: (i) the extent to which the fair value is less than cost and the cause for the fair value decline, (ii) the financial condition and near term prospects of the issuer, (iii) the length of time a security is in an unrealized loss position and (iv) the Company’s ability to hold the security for a period of time sufficient to allow for any anticipated recovery in fair value. There were no other-than-temporary impairments recognized during the years ended December 31, 2024, 2023, and 2022.
Inventory	Inventory Inventories consist of supplies such as reagents, plates, and testing kits, which are consumed when providing test results, and therefore the Company does not maintain finished goods inventory. Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard cost, which approximates actual cost on a first-in first-out basis.
Trade Accounts Receivable	Trade Accounts Receivable Trade accounts receivable represents estimated receivables from customers for revenue recognized related to the Company's tests. The Company does not have any off-balance-sheet credit exposure related to its customers and does not require collateral.
Property, Plant and Equipment	Property, Plant and Equipment Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method based on the lesser of estimated useful lives of the related assets or lease terms. Equipment items have depreciable lives of five four
Leases	Leases The Company acts as the lessee in its lease agreements, which primarily include operating leases for corporate offices, laboratory space, warehouse space, and certain laboratory and office equipment. The Company determines whether an arrangement is, or contains, a lease at inception and whether the lease should be classified as a finance or operating lease. For all leases, the Company records the present value of lease payments as right-of-use (“ROU”) assets and lease liabilities on the Consolidated Balance Sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments based on the present value of lease payments over the lease term. Classification of lease liabilities as either current or non-current is based on the expected timing of payments due under the Company’s obligations. As most of the Company’s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The ROU asset also consists of any lease incentives received. The lease terms used to calculate the ROU asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. The leases have remaining lease terms of one year to 14 years, some of which include options to extend the lease term for up to 10 years. The Company has taken advantage of certain practical expedients offered to registrants at adoption of Accounting Standards Codification ("ASC") 842, Leases . Lease expense for leases with a term of 12 months or less is recognized on a straight-line basis and is not included in the recognized ROU assets and lease liabilities. Further, as a practical expedient, all lease contracts are accounted for as one single lease component, as opposed to separating lease and non-lease components to allocate the consideration within a single lease contract. Operating leases are included in Operating lease right-of-use assets, Current maturities of operating lease liabilities, and Noncurrent operating lease liabilities in the Consolidated Balance Sheets. Finance leases are included in Other assets, Accrued liabilities, and Other long-term liabilities in the Consolidated Balance Sheets.
Intangible Assets	Intangible Assets
Other Long-Lived Assets	Other Long-Lived Assets
Goodwill	Goodwill Goodwill is tested for impairment by reporting unit on an annual basis as of October 1 and in the interim if events and circumstances indicate that goodwill may be impaired. The events and circumstances that are considered include business climate and market conditions, legal factors, operating performance indicators, and competition. Impairment of goodwill is first assessed using a qualitative approach. If the qualitative assessment suggests that impairment is more likely than not, a quantitative analysis is performed. The quantitative analysis involves a comparison of the fair value of the reporting unit with its carrying amount. If the carrying amount of a reporting unit exceeds its fair value, an impairment loss is recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to that reporting unit. If an event occurs that would cause a revision to the estimates and assumptions used in analyzing the value of the goodwill, the revision could result in a non-cash impairment charge that could have a material impact on the financial results.
Business Acquisitions/Divestitures	Business Acquisitions/Divestitures The Company accounts for acquisitions of entities that include inputs and processes and have the ability to create outputs as business combinations. The tangible and identifiable intangible assets acquired and liabilities assumed in a business combination are recorded based on their estimated fair values as of the business combination date, including identifiable intangible assets which either arise from a contractual or legal right or are separable from goodwill. The Company bases the estimated fair value of identifiable intangible assets acquired in a business combination on third-party valuations that use information and assumptions provided by the Company's management, which consider the Company's estimates of inputs and assumptions that a market participant would use. Any excess purchase price over the estimated fair value assigned to the net tangible and identifiable intangible assets acquired and liabilities assumed is recorded to goodwill. To the extent the fair value of the net assets and liabilities acquired exceeds the purchase price, a gain is recognized. In circumstances where an acquisition involves a contingent consideration arrangement that meets the definition of a liability under ASC 480, Distinguishing Liabilities from Equity , the Company recognizes a liability equal to the fair value of the contingent payments expected to be made as of the acquisition date. This liability is remeasured each reporting period and the changes in the fair value are recognized in General and administrative expenses in the Consolidated Statements of Operations. The Company evaluates its portfolio of businesses on an ongoing basis to ensure alignment with its strategic objectives and to enhance shareholder value. From time to time, the Company may divest certain businesses, product lines, or other non-core assets. Gains or losses from the sale of businesses or assets are included in Goodwill and long-lived asset impairment charges on the Company’s Consolidated Statements of Operations. See Note 16 for further information. Transaction costs associated with acquisitions are expensed as incurred in General and administrative expenses in the Consolidated Statements of Operations. Results of operations and cash flows of acquired companies are included in the operating results from the date of acquisition.
Revenue Recognition	Revenue Recognition The Company primarily generates revenue by performing molecular testing, primarily derived from the following categories of products: Hereditary Cancer (MyRisk and BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, Precise Tumor, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). Revenue is recorded at the estimated transaction price. Control is transferred, and revenue is recognized, once test results are released to the healthcare provider and/or patient. Under ASC 606, Revenue from Contracts with Customers (“ASC 606”), an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing tests and releasing the test results to customers, in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its agreements wherein the Company’s right to payment is in an amount that directly corresponds with the value of the Company’s performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration to be received. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. The estimate of revenue is affected by, among other factors, assumptions for changes in payor mix, payor collections, current customer contractual requirements, experience with collections from third-party payors, and changes in medical policies. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenue in the Consolidated Statements of Operations and Comprehensive Loss. In accordance with ASC 606, the Company has elected to exclude from the measurement of transaction price all taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction and collected by the Company from a customer for sales tax, value added tax, and certain other taxes.
Advertising Costs	Advertising Costs
Stock-based Payment Expense	Stock-based Payment Expense We recognize the fair value compensation cost relating to stock-based payment transactions in accordance with ASC 718, Compensation – Stock Compensation ("ASC 718"). Under the provisions of ASC 718, stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized over the employee’s requisite service period, which is generally the vesting period. Compensation cost for awards with only service conditions are recognized on a straight-line basis over the requisite service period. The fair value of restricted stock units ("RSUs") and performance restricted stock units ("PSUs") that do not have market conditions is based on the number of shares granted and the quoted price of the Company’s common stock on the grant date. The fair value of PSU awards that have market conditions is determined using the Monte Carlo Method. For PSUs, t he Company estimates the likelihood of achievement of the performance conditions at the end of each period. Forfeitures are recognized as a reduction of compensation expense in earnings in the period in which they occur. The fair value of shares issued under the Company's Employee Stock Purchase Plan is calculated using the Black-Scholes option-pricing model, based on assumptions including the risk-free interest rate, expected life, expected dividend yield and expected volatility. The average risk-free interest rate is determined using the U.S. Treasury rate. We determine the expected life based on the offering period of the Employee Stock Purchase Plan. The expected volatility is determined using the weighted average of daily historical volatility of the price of the Company's common stock.
Income Taxes	Income Taxes The Company recognizes income taxes under the asset and liability method. This approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The provision for income taxes, including the effective tax rate and analysis of potential tax exposure items requires significant judgment and expertise in federal, state, and foreign income tax laws, regulations and strategies, including the determination of deferred tax assets and liabilities and any estimated valuation allowances deemed necessary to recognize deferred tax assets at an amount that is more likely than not to be realized. The Company’s filings, including the positions taken therein, are subject to audit by various taxing authorities. While the Company believes it has provided adequately for its income tax liabilities in the Consolidated Financial Statements, adverse determinations by these taxing authorities could have a material adverse effect on the Company's consolidated financial condition, results of operations, or cash flows.
Earnings Per Share	Earnings Per Share Basic earnings per share ("EPS") is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. The following is a reconciliation of the denominators of the basic and diluted earnings per share computations: Years Ended December 31, (in millions) 2024 2023 2022 Denominator: Weighted-average shares outstanding used to compute basic EPS 90.6 82.8 80.6 Effect of dilutive stock options and RSUs — — — Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 90.6 82.8 80.6 Certain outstanding options and RSUs were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows: Years Ended December 31, (in millions) 2024 2023 2022 Anti-dilutive options and RSUs excluded from EPS computation 6.0 5.1 4.4
Foreign Currency	Foreign Currency The functional currency of the Company’s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholders’ equity.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Standards In November 2023, the Financial Accounting Standards Board ("FASB") issued accounting standards update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures , which enhances the disclosures required for reportable segments in annual and interim consolidated financial statements. ASU 2023-07 is effective for the Company for annual reporting periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. The Company has adopted the required disclosures effective for the year ended December 31, 2024. The Company has identified consolidated net income (loss) as the measure of segment profitability. The significant expenses presented to the chief operating decision maker ("CODM") are at the same level as presented in Consolidated Statement Operations in these financial statements. Standards Effective in Future Years and Not Yet Adopted In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures , which requires enhanced income tax disclosures, including disaggregation of information on the rate reconciliation table and disaggregated information related to income taxes paid. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on its income tax disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses , requiring public entities to disclose additional information about specific expense categories in the notes to the financial statements on an interim and annual basis. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and for interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03.
Fair Value Measurements	The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilized broker quotes in a non-active market for valuation of these securities. Level 3—unobservable inputs. All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information.

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Schedule of Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Consolidated Balance Sheets that agrees to the amounts included in the Consolidated Statement of Cash Flows. December 31, (in millions) 2024 2023 2022 Cash and cash equivalents $ 102.4 $ 132.1 $ 56.9 Restricted cash 9.5 8.8 9.5 Total cash, cash equivalents, and restricted cash $ 111.9 $ 140.9 $ 66.4
Schedule of Cash and Cash Equivalents	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Consolidated Balance Sheets that agrees to the amounts included in the Consolidated Statement of Cash Flows. December 31, (in millions) 2024 2023 2022 Cash and cash equivalents $ 102.4 $ 132.1 $ 56.9 Restricted cash 9.5 8.8 9.5 Total cash, cash equivalents, and restricted cash $ 111.9 $ 140.9 $ 66.4
Schedule of Revenue by Type	The following table presents detail regarding the composition of the Company’s total revenue by product type for the years ended December 31, 2024, 2023, and 2022: Years Ended December 31, (In millions) 2024 2023 2022 Hereditary Cancer $ 364.5 $ 327.8 $ 305.5 Tumor Profiling 125.8 135.6 128.6 Prenatal 177.1 151.3 116.4 Pharmacogenomics 170.2 138.5 127.6 Autoimmune — — 0.3 Total revenue $ 837.6 $ 753.2 $ 678.4
Schedule of Revenue by Geographical Region	In addition, the following tables reconcile revenue by geographical region, either U.S. or rest of world ("RoW"), to total revenue: Years Ended December 31, 2024 2023 2022 (in millions) U.S. RoW Total U.S. RoW Total U.S. RoW Total Hereditary Cancer $ 318.6 $ 45.9 $ 364.5 $ 280.5 $ 47.3 $ 327.8 $ 263.5 $ 42.0 $ 305.5 Tumor Profiling 104.2 21.6 125.8 102.1 33.5 135.6 84.5 44.1 128.6 Prenatal 176.5 0.6 177.1 150.6 0.7 151.3 115.6 0.8 116.4 Pharmacogenomics 170.2 — 170.2 138.5 — 138.5 127.6 — 127.6 Autoimmune — — — — — — 0.3 — 0.3 Total revenue $ 769.5 $ 68.1 $ 837.6 $ 671.7 $ 81.5 $ 753.2 $ 591.5 $ 86.9 $ 678.4
Schedule of Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations	The following is a reconciliation of the denominators of the basic and diluted earnings per share computations: Years Ended December 31, (in millions) 2024 2023 2022 Denominator: Weighted-average shares outstanding used to compute basic EPS 90.6 82.8 80.6 Effect of dilutive stock options and RSUs — — — Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 90.6 82.8 80.6
Schedule of Potential Dilutive Common Shares	These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows: Years Ended December 31, (in millions) 2024 2023 2022 Anti-dilutive options and RSUs excluded from EPS computation 6.0 5.1 4.4
Schedule of Cumulative Translation Adjustments Included in Accumulated Other Comprehensive Loss	The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions): Ending balance December 31, 2023 $ (3.7) Period translation adjustments (3.0) Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax 5.9 Ending balance December 31, 2024 $ (0.8)

MARKETABLE INVESTMENT SECURIT_2

MARKETABLE INVESTMENT SECURITIES (Tables)	12 Months Ended
	Dec. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security	The amortized cost, gross unrealized holding losses, and fair value for debt securities classified as available-for-sale securities by major security type and class of security at December 31, 2023 were as follows: (in millions) Amortized Gross Estimated December 31, 2023: Cash and cash equivalents: Cash $ 129.9 $ — $ 129.9 Cash equivalents 2.2 — 2.2 Total cash and cash equivalents 132.1 — 132.1 Available-for-sale: Corporate bonds and notes 8.4 (0.1) 8.3 Municipal bonds 0.5 — 0.5 Total $ 141.0 $ (0.1) $ 140.9

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Financial Assets and Liabilities	The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis as of December 31, 2023: (in millions) Level 1 Level 2 Level 3 Total December 31, 2023 Money market funds (a) $ 2.2 $ — $ — $ 2.2 Corporate bonds and notes — 8.3 — 8.3 Municipal bonds — 0.5 — 0.5 Contingent consideration — — (5.4) (5.4) Total $ 2.2 $ 8.8 $ (5.4) $ 5.6 (a) Money market funds are primarily comprised of exchange traded funds and accrued interest.
Change in Fair Value of Contingent Consideration	The following table reconciles the change in the fair value of the contingent consideration during the periods presented: (in millions) Years Ended December 31, 2024 2023 2022 Carrying amount at beginning of period $ 5.4 $ 6.8 $ 8.6 Payment of contingent consideration (5.8) — (3.0) Consideration recognized at acquisition — — 2.1 Change in fair value recognized in the statement of operations 0.4 (1.5) (0.4) Translation adjustments recognized in other comprehensive income (loss) — 0.1 (0.5) Carrying amount at end of period $ — $ 5.4 $ 6.8

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	The property, plant and equipment were as follows: December 31, (in millions) 2024 2023 Leasehold improvements $ 78.5 $ 91.3 Equipment 148.5 147.6 Property, plant and equipment, gross 227.0 238.9 Less accumulated depreciation (109.6) (119.9) Property, plant and equipment, net $ 117.4 $ 119.0 The Company recorded depreciation during the respective periods as follows: Years Ended December 31, (in millions) 2024 2023 2022 Depreciation expense $ 19.5 $ 19.1 $ 11.6

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill	The changes in the carrying amount of goodwill for the year ended December 31, 2024 are as follows: (in millions) Year Ended December 31, 2024 Beginning balance $ 287.4 Goodwill impairment (0.8) Translation adjustments (0.3) Ending balance $ 286.3
Schedule of Amortizable Intangible Assets	The following tables summarize the amounts reported as intangible assets: (in millions) Gross Accumulated Net Weighted-Average Useful Life Weighted-Average Remaining Useful Life At December 31, 2024 Developed technologies $ 560.1 $ (326.5) $ 233.6 10.6 3.6 Internal-use software 1.8 (0.7) 1.1 3.0 1.9 Customer relationships 1.6 (0.3) 1.3 10.0 7.8 Trademarks 6.1 (1.3) 4.8 10.0 7.8 Internal-use software (in-process) 21.6 — 21.6 Total intangible assets $ 591.2 $ (328.8) $ 262.4 (in millions) Gross Accumulated Net Weighted-Average Useful Life Weighted-Average Remaining Useful Life At December 31, 2023 Developed technologies $ 626.1 $ (295.3) $ 330.8 14.4 8.1 Internal-use software 0.8 (0.1) 0.7 3.0 2.5 Customer relationships 1.6 (0.2) 1.4 10.0 8.8 Trademarks 6.1 (0.7) 5.4 10.0 8.8 Internal-use software (in-process) 11.2 — 11.2 Total intangible assets $ 645.8 $ (296.3) $ 349.5
Schedule of Recorded Amortization for Intangible Assets	The Company recorded amortization during the respective periods for intangible assets as follows: Years Ended December 31, (in millions) 2024 2023 2022 Amortization of intangible assets $ 42.1 $ 42.8 $ 41.1
Schedule of Future Amortization Expense of Intangible Assets	Future amortization expense of intangible assets as of December 31, 2024 is estimated to be as follows (in millions): Years Ended December 31, Amortization Expense 2025 $ 37.4 2026 37.2 2027 36.8 2028 36.7 2029 36.7 Thereafter 77.6 Total $ 262.4

ACCRUED LIABILITIES (Tables)

ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accrued liabilities consist of the following: December 31, (in millions) 2024 2023 Employee compensation and benefits $ 57.4 $ 49.7 Accrued taxes payable 5.1 4.6 Refunds payable and reserves 19.9 20.1 Short-term contingent consideration — 3.1 Accrued royalties 6.5 5.3 Legal settlement 2.8 6.0 Lease termination accrual 3.8 4.4 Escrow liability 7.5 — Other accrued liabilities 16.0 20.7 Total accrued liabilities $ 119.0 $ 113.9
Summary of Changes in Reserve for Recoupment	The following table summarizes the balance and activity of the refunds payable and reserves for the years ended December 31, 2024 and 2023: Years Ended December 31, (in millions) 2024 2023 Beginning balance $ 20.1 $ 19.3 Recoupments paid (11.3) (13.8) Additions to the reserve 11.1 14.6 Ending balance $ 19.9 $ 20.1

OTHER LONG-TERM LIABILITIES (Ta

OTHER LONG-TERM LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2024
Other Liabilities Disclosure [Abstract]
Schedule of Other Long-Term Liabilities	The Company's other long-term liabilities were as follows: December 31, (in millions) 2024 2023 Contingent consideration $ — $ 2.3 Escrow liability — 7.5 Legal settlements — 24.0 Other 2.2 7.5 Total other long-term liabilities $ 2.2 $ 41.3

PREFERRED AND COMMON STOCKHOL_2

PREFERRED AND COMMON STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Schedule of Shares of Common Stock Issued and Outstanding	Shares of common stock issued and outstanding Years Ended December 31, (in millions) 2024 2023 2022 Beginning common stock issued and outstanding 89.9 81.2 80.0 Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans 1.4 1.3 1.2 Common stock issued for public offering — 7.4 — Common stock issued and outstanding at end of period 91.3 89.9 81.2

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	A summary of the stock option activity under the Company's inducement awards for the twelve months ended December 31, 2024 is as follows: (number of shares in millions) Number Weighted Weighted Options outstanding at December 31, 2023 0.7 $ 13.38 Options outstanding at December 31, 2024 0.7 13.38 2.62 Options exercisable at December 31, 2024 0.5 13.38 2.62 Options vested and expected to vest 0.2 $ 13.38 2.62
Schedule of Restricted Stock Units Activity	A summary of the RSU awards activity under the Company's equity plans and inducement awards, including PSU awards, for the year ended December 31, 2024 is as follows: (number of shares in millions) Number Weighted RSUs unvested and outstanding at December 31, 2023 4.4 $ 24.37 RSUs granted 2.7 $ 22.09 Less: RSUs vested (1.6) $ 22.98 RSUs canceled (0.2) $ 23.58 RSUs unvested and outstanding at December 31, 2024 5.3 $ 23.66
Schedule of Stock-Based Compensation Expense	Stock-based compensation expense recognized and included in the Consolidated Statements of Operations was allocated as follows: Years Ended December 31, (in millions) 2024 2023 2022 Cost of revenue $ 1.6 $ 1.4 $ 1.7 Research and development expense 8.8 4.0 5.2 Sales and marketing expense 9.0 7.2 6.2 General and administrative expense 30.4 28.1 25.0 Total stock-based compensation expense $ 49.8 $ 40.7 $ 38.1
Schedule of Aggregate Intrinsic Value	The aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows: (in millions) December 31, 2024 Aggregate intrinsic value of options outstanding $ 0.2 Aggregate intrinsic value of options fully vested 0.2 Aggregate intrinsic value of RSUs outstanding 71.7
Schedule of Shares Purchased and Compensation Expenses for ESPP	Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the periods reported are as follows: Years Ended December 31, (in millions) 2024 2023 2022 Shares purchased under the plan 0.4 0.4 0.3 Plan compensation expense $ 2.1 $ 2.2 $ 1.9
Schedule of Valuation Assumptions for ESPP	The fair value of shares issued under the Amended and Restated 2012 Purchase Plan that was in effect for each period reported was calculated using the Black‑Scholes option-pricing model using the weighted-average assumptions below. Each of these inputs is subjective and its determination generally requires significant judgment. Years Ended December 31, 2024 2023 2022 Risk-free interest rate 5.3% 5.1% 1.4% Expected dividend yield —% —% —% Expected life (in years) 0.5 0.5 0.5 Expected volatility 50% 56% 53%

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Income Tax Benefit	Income tax expense (benefit) consists of the following: Years Ended December 31, (in millions) 2024 2023 2022 Current: Federal $ 3.4 $ 3.4 $ (0.5) State 1.5 1.8 1.9 Foreign 1.2 0.2 0.5 Total current 6.1 5.4 1.9 Deferred: Federal (15.5) (51.8) (25.8) State (5.5) (5.2) (4.8) Foreign 3.1 0.1 (2.9) Change in valuation allowance 15.6 52.6 3.0 Total deferred (2.3) (4.3) (30.5) Total income tax expense (benefit) $ 3.8 $ 1.1 $ (28.6)
Schedule of Loss Before Income Taxes	Loss before income taxes consists of the following: Years Ended December 31, (in millions) 2024 2023 2022 United States $ (125.4) $ (263.2) $ (141.3) Foreign 1.9 1.0 0.7 Total $ (123.5) $ (262.2) $ (140.6)
Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported	The differences between income taxes at the statutory federal income tax rate and income taxes reported in the Consolidated Statements of Operations were as follows: Years Ended December 31, (in millions) 2024 2023 2022 Federal income tax benefit at the statutory rate $ (25.9) 21.0 % $ (54.9) 21.0 % $ (29.5) 21.0 % State income taxes, net of federal benefit (2.4) 1.9 % (4.1) 1.6 % (3.3) 2.3 % Research and development credits (0.4) 0.3 % (1.6) 0.6 % (3.5) 2.5 % Uncertain tax positions 2.8 (2.3) % 3.7 (1.4) % 0.6 (0.4) % Stock-based incentive awards 0.8 (0.6) % 1.2 (0.5) % 2.5 (1.8) % Foreign rate differential 3.3 (2.7) % (0.4) 0.2 % — — % Change in valuation allowance 15.7 (12.7) % 52.6 (20.1) % 2.6 (1.8) % Non-deductible officer compensation 3.9 (3.2) % 3.0 (1.1) % 3.5 (2.5) % Acquisitions and dispositions 5.1 (4.1) % 0.1 — % (0.1) 0.1 % Other, net 0.9 (0.7) % 1.5 (0.7) % (1.4) 0.9 % Total income tax expense (benefit) $ 3.8 (3.1) % $ 1.1 (0.4) % $ (28.6) 20.3 %
Schedule of Components of Deferred Tax Assets and Liabilities	The significant components of the Company’s deferred tax assets and liabilities were comprised of the following: December 31, (in millions) 2024 2023 Deferred tax assets: Net operating loss carryforwards $ 62.7 $ 77.1 Stock compensation expense 6.6 5.0 Research and development credits 20.6 20.8 Lease liability 24.4 28.0 Capitalized research and development costs 54.3 38.4 Accrued expenses and liabilities 16.5 22.5 Other, net — 3.2 Total gross deferred tax assets 185.1 195.0 Less valuation allowance (111.9) (95.0) Total deferred tax assets 73.2 100.0 Deferred tax liabilities: Intangible assets 55.5 84.2 Lease right-of-use assets 13.3 15.5 Property, plant and equipment 3.2 1.9 Other, net 0.8 — Total deferred tax liabilities 72.8 101.6 Net deferred tax asset (liability) $ 0.4 $ (1.6)
Schedule of Net Operating Loss and Research Credit Carryforwards (Tax Effected)	At December 31, 2024, the Company had the following net operating loss and research credit carryforwards (tax effected), with their respective expiration periods. Certain carryforwards are subject to the limitations of Section 382 and 383 of the Internal Revenue Code as indicated: Carryforwards (in millions) Amount Subject to Sections 382, 383 Expires Through Federal net operating loss $ 32.2 Yes 2033 Indefinite Federal capital loss 13.8 No 2026 2029 Utah net operating loss 0.9 No Indefinite Indefinite California net operating loss 5.0 Yes 2029 2044 Other state net operating loss 6.3 Yes Various Various Foreign net operating losses (various jurisdictions) 4.3 No Various Various Federal research credit 10.5 Yes 2027 2044 Utah research credit 4.9 No 2024 2038 California research credit 5.2 No Indefinite Indefinite
Schedule of Unrecognized Tax Benefits	The Company’s gross unrecognized tax benefits as of the years ended December 31, 2024, 2023, and 2022, and the changes in those balances are as follows: Years Ended December 31, (in millions) 2024 2023 2022 Unrecognized tax benefits at the beginning of period $ 48.1 $ 43.9 $ 32.1 Gross increases - current year tax positions 1.0 0.8 12.9 Gross increases - prior year tax positions 2.6 3.6 1.6 Gross decreases - prior year tax positions — (0.2) (2.0) Gross decreases - settlements — — (0.7) Unrecognized tax benefits at end of year $ 51.7 $ 48.1 $ 43.9 Interest and penalties in year-end balance $ 8.8 $ 6.4 $ 4.1

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Maturities of Operating Lease Liabilities	As of December 31, 2024, the maturities of the Company’s operating lease liabilities were as follows: Year Ended (in millions) : 2025 $ 18.9 2026 12.3 2027 12.3 2028 12.4 2029 12.1 Thereafter 73.7 Total future lease payments 141.7 Less: amounts representing interest 41.0 Present value of future lease payments 100.7 Less: current maturities of operating lease liabilities (12.8) Noncurrent operating lease liabilities $ 87.9

EMPLOYEE DEFERRED SAVINGS PLAN

EMPLOYEE DEFERRED SAVINGS PLAN (Tables)	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Schedule of Contributions to the Plan	The Company’s recorded contributions to the plan are as follows: Years Ended December 31, (in millions) 2024 2023 2022 Deferred savings plan contributions $ 10.3 $ 10.0 $ 9.0

SEGMENT AND RELATED INFORMATI_2

SEGMENT AND RELATED INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	The Company's long-lived assets by geographical region are as follows: December 31, (in millions) 2024 2023 Long-lived assets: United States $ 728.1 $ 794.6 Rest of world 1.4 38.3 Total $ 729.5 $ 832.9

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2024
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Cash Flow Information	The Company's supplemental cash flow information for the respective periods are as follows: December 31, (in millions) 2024 2023 2022 Cash paid for income taxes $ 2.7 $ 1.9 $ 1.8 Cash paid for interest 1.9 1.4 — Non-cash investing and financing activities: Change in operating lease right-of-use assets and lease liabilities Operating lease right-of-use assets $ 3.1 $ (31.0) $ 46.9 Operating lease liabilities (3.1) 36.7 (46.9) Tenant improvement allowance not yet received — — 22.9 Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities 6.4 6.9 10.0

ORGANIZATION AND SUMMARY OF S_4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Restricted cash	$ 9,500,000	$ 8,800,000	$ 9,500,000
Restricted cash, current	8,600,000	1,200,000
Restricted cash, non current	$ 900,000	7,600,000
Lease extension term	10 years
Unamortized internal-use technology costs	$ 3,400,000	4,600,000
Revenue recognized	18,500,000	7,200,000	22,100,000
Recognized revenue due to a retroactive coverage change	3,000,000
Capitalized costs incurred to obtain or fulfill contract	0
Advertising costs	10,300,000	8,500,000	$ 5,300,000
Foreign currency transaction loss	$ 1,100,000	3,400,000
Minimum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Remaining lease terms	1 year
Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Remaining lease terms	14 years
Internal-use software
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Unamortized software costs	$ 22,700,000	$ 11,900,000
Equipment | Minimum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Estimated useful lives (in years)	5 years
Equipment | Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Estimated useful lives (in years)	7 years
Leasehold improvements | Minimum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Estimated useful lives (in years)	4 years
Leasehold improvements | Maximum
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Estimated useful lives (in years)	14 years
Government Contracts Concentration Risk | Medicare | Revenue from Contract with Customer Benchmark
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Concentration risk (in percent)	12%	12%	14%
Medicare | Medicare | Accounts Receivable
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]
Concentration risk (in percent)	18%	12%

ORGANIZATION AND SUMMARY OF S_5

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES -Schedule of Restricted Cash (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash and cash equivalents	$ 102.4	$ 132.1	$ 56.9
Restricted cash	9.5	8.8	9.5
Total cash, cash equivalents, and restricted cash	$ 111.9	$ 140.9	$ 66.4	$ 258.8

ORGANIZATION AND SUMMARY OF S_6

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Revenue by Type (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 837.6	$ 753.2	$ 678.4
Hereditary Cancer
Disaggregation of Revenue [Line Items]
Revenue	364.5	327.8	305.5
Tumor Profiling
Disaggregation of Revenue [Line Items]
Revenue	125.8	135.6	128.6
Prenatal
Disaggregation of Revenue [Line Items]
Revenue	177.1	151.3	116.4
Pharmacogenomics
Disaggregation of Revenue [Line Items]
Revenue	170.2	138.5	127.6
Autoimmune
Disaggregation of Revenue [Line Items]
Revenue	$ 0	$ 0	$ 0.3

ORGANIZATION AND SUMMARY OF S_7

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Revenue by Geographical Region (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Revenue	$ 837.6	$ 753.2	$ 678.4
Hereditary Cancer
Disaggregation of Revenue [Line Items]
Revenue	364.5	327.8	305.5
Tumor Profiling
Disaggregation of Revenue [Line Items]
Revenue	125.8	135.6	128.6
Prenatal
Disaggregation of Revenue [Line Items]
Revenue	177.1	151.3	116.4
Pharmacogenomics
Disaggregation of Revenue [Line Items]
Revenue	170.2	138.5	127.6
Autoimmune
Disaggregation of Revenue [Line Items]
Revenue	0	0	0.3
United States
Disaggregation of Revenue [Line Items]
Revenue	769.5	671.7	591.5
United States | Hereditary Cancer
Disaggregation of Revenue [Line Items]
Revenue	318.6	280.5	263.5
United States | Tumor Profiling
Disaggregation of Revenue [Line Items]
Revenue	104.2	102.1	84.5
United States | Prenatal
Disaggregation of Revenue [Line Items]
Revenue	176.5	150.6	115.6
United States | Pharmacogenomics
Disaggregation of Revenue [Line Items]
Revenue	170.2	138.5	127.6
United States | Autoimmune
Disaggregation of Revenue [Line Items]
Revenue	0	0	0.3
Rest of world
Disaggregation of Revenue [Line Items]
Revenue	68.1	81.5	86.9
Rest of world | Hereditary Cancer
Disaggregation of Revenue [Line Items]
Revenue	45.9	47.3	42
Rest of world | Tumor Profiling
Disaggregation of Revenue [Line Items]
Revenue	21.6	33.5	44.1
Rest of world | Prenatal
Disaggregation of Revenue [Line Items]
Revenue	0.6	0.7	0.8
Rest of world | Pharmacogenomics
Disaggregation of Revenue [Line Items]
Revenue	0	0	0
Rest of world | Autoimmune
Disaggregation of Revenue [Line Items]
Revenue	$ 0	$ 0	$ 0

ORGANIZATION AND SUMMARY OF S_8

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Earnings Per Share (Details) - shares shares in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Weighted-average shares outstanding used to compute basic EPS (in shares)	90.6	82.8	80.6
Effect of dilutive stock option and RSUs (in shares)	0	0	0
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS (in shares)	90.6	82.8	80.6
Anti-dilutive options and RSUs excluded from EPS computation (in shares)	6	5.1	4.4

ORGANIZATION AND SUMMARY OF S_9

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Foreign Currency Cumulative Translation Adjustments (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 783.2	$ 885.8	$ 967.8
Period translation adjustments	(3)	2.1	(1.3)
Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax	(5.8)	(0.4)	0
Ending balance	701.1	783.2	$ 885.8
Accumulated Foreign Currency Adjustment Attributable to Parent
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(3.7)
Period translation adjustments	(3)
Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax	5.9
Ending balance	$ (0.8)	$ (3.7)

MARKETABLE INVESTMENT SECURIT_3

MARKETABLE INVESTMENT SECURITIES - Narrative (Details)	12 Months Ended
	Dec. 31, 2023 USD ($) position	Dec. 31, 2022 USD ($)	Dec. 31, 2024 USD ($)
Investments, Debt and Equity Securities [Abstract]
Investment securities			$ 0
Gross unrealized holding gains	$ 0
Investment sold	90,400,000	$ 28,400,000
Realized losses	$ 1,500,000
Debt securities, available-for-sale, in unrealized loss position | position	7
Debt securities, available-for-sale, unrealized loss position, accumulated loss	$ (100,000)
Available-for-sale securities, gross unrealized loss, fair market value	$ 8,800,000

MARKETABLE INVESTMENT SECURIT_4

MARKETABLE INVESTMENT SECURITIES - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents
Amortized cost	$ 102,400,000	$ 132,100,000	$ 56,900,000
Estimated fair value		132,100,000
Available-for-Sale
Gross unrealized holding losses		(100,000)
Estimated fair value	$ 0
Total
Amortized cost		141,000,000
Estimated fair value		140,900,000
Corporate bonds and notes
Available-for-Sale
Amortized cost		8,400,000
Gross unrealized holding losses		(100,000)
Estimated fair value		8,300,000
Municipal bonds
Available-for-Sale
Amortized cost		500,000
Gross unrealized holding losses		0
Estimated fair value		500,000
Cash
Cash and Cash Equivalents
Amortized cost		129,900,000
Estimated fair value		129,900,000
Cash equivalents
Cash and Cash Equivalents
Amortized cost		2,200,000
Estimated fair value		$ 2,200,000

FAIR VALUE MEASUREMENTS - Narra

FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Balance Sheet Grouping [Line Items]
Financial assets requiring fair value re-measurement	$ 0	$ 5,600,000
Gateway Genomics, LLC
Fair Value, Balance Sheet Grouping [Line Items]
Contingent consideration liability	0
Level 2
Fair Value, Balance Sheet Grouping [Line Items]
Estimated fair value of long-term debt	$ 40,200,000
Financial assets requiring fair value re-measurement		$ 8,800,000

FAIR VALUE MEASUREMENTS - Sched

FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Financial Assets and Liabilities (Details) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total	$ 0	$ 5,600,000
Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets		2,200,000
Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets		8,300,000
Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets		500,000
Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities		(5,400,000)
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total		2,200,000
Level 1 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets		2,200,000
Level 1 | Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets		0
Level 1 | Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets		0
Level 1 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities		0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total		8,800,000
Level 2 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets		0
Level 2 | Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets		8,300,000
Level 2 | Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets		500,000
Level 2 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities		0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total		(5,400,000)
Level 3 | Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets		0
Level 3 | Corporate bonds and notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets		0
Level 3 | Municipal bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets		0
Level 3 | Contingent consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities		$ (5,400,000)

FAIR VALUE MEASUREMENTS - Sch_2

FAIR VALUE MEASUREMENTS - Schedule of Change in Fair Value of Contingent Consideration (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 5.4	$ 6.8	$ 8.6
Payment of contingent consideration	(5.8)	0	(3)
Consideration recognized at acquisition	0	0	2.1
Change in fair value recognized in the statement of operations	0.4	(1.5)	(0.4)
Translation adjustments recognized in other comprehensive income (loss)	0	0.1	(0.5)
Ending balance	$ 0	$ 5.4	$ 6.8
Fair value, recurring basis, unobservable input reconciliation, gain (loss), statement of income	Change in fair value recognized in the statement of operations	Change in fair value recognized in the statement of operations	Change in fair value recognized in the statement of operations

PROPERTY, PLANT AND EQUIPMENT_3

PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Balances (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 227	$ 238.9
Less accumulated depreciation	(109.6)	(119.9)
Property, plant and equipment, net	117.4	119
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	78.5	91.3
Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 148.5	$ 147.6

PROPERTY, PLANT AND EQUIPMENT_4

PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)
Leasehold improvements
Property, Plant and Equipment [Line Items]
Accelerated depreciation	$ 5.7

PROPERTY, PLANT AND EQUIPMENT_5

PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Depreciation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 19.5	$ 19.1	$ 11.6

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Schedule of Carrying Amount of Goodwill (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill [Roll Forward]
Beginning balance		$ 287,400,000
Goodwill impairment	$ (800,000)		$ 0	$ 0
Translation adjustments		(300,000)
Ending balance		$ 286,300,000	$ 287,400,000

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2024	Jun. 30, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill And Intangible Assets [Line Items]
Goodwill impairment charge		$ 800,000		$ 0	$ 0
Risk-adjusted cost of capital percentage	10%
Intangible assets impairment charge				$ 0	$ 0
Impairment, intangible asset, finite-lived, statement of income or comprehensive income			Goodwill and long-lived asset impairment charges	Goodwill and long-lived asset impairment charges	Goodwill and long-lived asset impairment charges
Fair value of intangible assets	$ 262,400,000		$ 262,400,000	$ 349,500,000
Capitalized projects	591,200,000		591,200,000	645,800,000
Developed technologies
Goodwill And Intangible Assets [Line Items]
Fair value of intangible assets	$ 233,600,000		$ 233,600,000	$ 330,800,000
Estimated remaining useful life	10 years 7 months 6 days		10 years 7 months 6 days	14 years 4 months 24 days
Capitalized projects	$ 560,100,000		$ 560,100,000	$ 626,100,000
Developed technologies | Pharmacogenomics
Goodwill And Intangible Assets [Line Items]
Intangible assets impairment charge			43,000,000
Fair value of intangible assets	$ 89,000,000		$ 89,000,000
Developed technologies | Minimum
Goodwill And Intangible Assets [Line Items]
Estimated remaining useful life	5 years		5 years
Developed technologies | Maximum
Goodwill And Intangible Assets [Line Items]
Estimated remaining useful life	12 years		12 years
Internal-use software (in-process)
Goodwill And Intangible Assets [Line Items]
Fair value of intangible assets	$ 21,600,000		$ 21,600,000	11,200,000
Capitalized projects	21,600,000		21,600,000	11,200,000
Customer relationships
Goodwill And Intangible Assets [Line Items]
Fair value of intangible assets	$ 1,300,000		$ 1,300,000	$ 1,400,000
Estimated remaining useful life	10 years		10 years	10 years
Capitalized projects	$ 1,600,000		$ 1,600,000	$ 1,600,000
Estimated acquired useful lives (in years)			8 years
Trademarks
Goodwill And Intangible Assets [Line Items]
Fair value of intangible assets	$ 4,800,000		$ 4,800,000	$ 5,400,000
Estimated remaining useful life	10 years		10 years	10 years
Capitalized projects	$ 6,100,000		$ 6,100,000	$ 6,100,000
Estimated acquired useful lives (in years)			8 years
Internal-use software
Goodwill And Intangible Assets [Line Items]
Fair value of intangible assets	$ 1,100,000		$ 1,100,000	$ 700,000
Estimated remaining useful life	3 years		3 years	3 years
Capitalized projects	$ 1,800,000		$ 1,800,000	$ 800,000

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Intangible Assets [Line Items]
Gross Carrying Amount	$ 591.2	$ 645.8
Accumulated Amortization	(328.8)	(296.3)
Total	262.4	349.5
Developed technologies
Intangible Assets [Line Items]
Gross Carrying Amount	560.1	626.1
Accumulated Amortization	(326.5)	(295.3)
Total	$ 233.6	$ 330.8
Weighted-Average Useful Life (in Years)	10 years 7 months 6 days	14 years 4 months 24 days
Weighted-Average Remaining Useful Life (in Years)	3 years 7 months 6 days	8 years 1 month 6 days
Internal-use software
Intangible Assets [Line Items]
Gross Carrying Amount	$ 1.8	$ 0.8
Accumulated Amortization	(0.7)	(0.1)
Total	$ 1.1	$ 0.7
Weighted-Average Useful Life (in Years)	3 years	3 years
Weighted-Average Remaining Useful Life (in Years)	1 year 10 months 24 days	2 years 6 months
Customer relationships
Intangible Assets [Line Items]
Gross Carrying Amount	$ 1.6	$ 1.6
Accumulated Amortization	(0.3)	(0.2)
Total	$ 1.3	$ 1.4
Weighted-Average Useful Life (in Years)	10 years	10 years
Weighted-Average Remaining Useful Life (in Years)	7 years 9 months 18 days	8 years 9 months 18 days
Trademarks
Intangible Assets [Line Items]
Gross Carrying Amount	$ 6.1	$ 6.1
Accumulated Amortization	(1.3)	(0.7)
Total	$ 4.8	$ 5.4
Weighted-Average Useful Life (in Years)	10 years	10 years
Weighted-Average Remaining Useful Life (in Years)	7 years 9 months 18 days	8 years 9 months 18 days
Internal-use software (in-process)
Intangible Assets [Line Items]
Gross Carrying Amount	$ 21.6	$ 11.2
Accumulated Amortization	0	0
Total	$ 21.6	$ 11.2

GOODWILL AND INTANGIBLE ASSET_5

GOODWILL AND INTANGIBLE ASSETS - Schedule of Amortization on Intangible Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 42.1	$ 42.8	$ 41.1

GOODWILL AND INTANGIBLE ASSET_6

GOODWILL AND INTANGIBLE ASSETS - Schedule of Future Amortization Expense (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Future Amortization Expense
2025	$ 37.4
2026	37.2
2027	36.8
2028	36.7
2029	36.7
Thereafter	77.6
Total	$ 262.4	$ 349.5

ACCRUED LIABILITIES - Summary (

ACCRUED LIABILITIES - Summary (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 57.4	$ 49.7
Accrued taxes payable	5.1	4.6
Refunds payable and reserves	19.9	20.1	$ 19.3
Short-term contingent consideration	0	3.1
Accrued royalties	6.5	5.3
Legal settlement	2.8	6
Lease termination accrual	3.8	4.4
Escrow liability	7.5	0
Other accrued liabilities	16	20.7
Total accrued liabilities	$ 119	$ 113.9

ACCRUED LIABILITIES - Changes i

ACCRUED LIABILITIES - Changes in Reserve for Recoupment (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Refunds Payable And Reserve [Roll Forward]
Beginning balance	$ 20.1	$ 19.3
Recoupments paid	(11.3)	(13.8)
Additions to the reserve	11.1	14.6
Ending balance	$ 19.9	$ 20.1

LONG-TERM DEBT (Details)

LONG-TERM DEBT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Oct. 31, 2023	Jun. 30, 2023
Debt Instrument [Line Items]
Financial covenant compliance	Company was compliant with all such financial covenants	Company was compliant with all such financial covenants
ABL Facility | Line of Credit
Debt Instrument [Line Items]
Current availability	$ 56,000,000
Revolving Credit Facility | Line of Credit
Debt Instrument [Line Items]
Availability threshold amount	12,500,000
Revolving Credit Facility | ABL Facility | Line of Credit
Debt Instrument [Line Items]
Maximum aggregate principal commitment				$ 90,000,000
Line of credit, increase in maximum principal upon request			$ 25,000,000
Increase principal commitment			$ 115,000,000
Outstanding balances	39,600,000	$ 38,500,000
Debt issuance costs	$ 900,000	$ 1,500,000
Line of credit facility, borrowing base, percent of eligible accounts receivable plus certain cash held	85%
Line of credit facility, borrowing base, eligible cash held	$ 20,000,000
Line of credit facility, borrowing base, eligible cash collections, period	60 days
Weighted average interest rate	7.80%	9.75%
Fixed charge ratio, minimum	1
Line of credit facility, commitment fee amount	$ 10,600,000
Line of credit facility, commitment fee percentage	12.50%
Availability threshold amount	$ 12,500,000
Debt instrument, maximum amount borrowing base period	45 days
Revolving Credit Facility | ABL Facility | Line of Credit | Minimum
Debt Instrument [Line Items]
Undrawn fee (percent)	0.375%
Availability threshold, percentage of maximum commitment amount	15%
Revolving Credit Facility | ABL Facility | Line of Credit | Maximum
Debt Instrument [Line Items]
Undrawn fee (percent)	0.50%
Availability threshold, percentage of maximum commitment amount	15%
Revolving Credit Facility | ABL Facility | New York Federal Reserve Bank Rate | Line of Credit | Variable Rate, Scenario One
Debt Instrument [Line Items]
Basis spread on rate (percent)	0.50%
Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Line of Credit | Variable Rate, Scenario One
Debt Instrument [Line Items]
Basis spread on rate (percent)	1%
Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Line of Credit | Variable Rate, Scenario One | Minimum
Debt Instrument [Line Items]
Basis spread on rate (percent)	1%
Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Line of Credit | Variable Rate, Scenario One | Maximum
Debt Instrument [Line Items]
Basis spread on rate (percent)	1.50%
Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Line of Credit | Variable Rate, Scenario Two
Debt Instrument [Line Items]
Basis spread on rate (percent)	0.10%
Floor rate (percent)	0%
Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Line of Credit | Variable Rate, Scenario Two | Minimum
Debt Instrument [Line Items]
Basis spread on rate (percent)	2%
Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Line of Credit | Variable Rate, Scenario Two | Maximum
Debt Instrument [Line Items]
Basis spread on rate (percent)	2.50%
Revolving Credit Facility | ABL Facility | ABR Floor | Line of Credit | Variable Rate, Scenario Two
Debt Instrument [Line Items]
Floor rate (percent)	1%

OTHER LONG-TERM LIABILITIES - S

OTHER LONG-TERM LIABILITIES - Schedule of Other Long-Term Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Other Liabilities Disclosure [Abstract]
Contingent consideration	$ 0	$ 2.3
Escrow liability	0	7.5
Legal settlements	0	24
Other	2.2	7.5
Total other long-term liabilities	$ 2.2	$ 41.3

OTHER LONG-TERM LIABILITIES - N

OTHER LONG-TERM LIABILITIES - Narrative (Details) - Raygen, Inc Versus Myriad Women's Health, Inc. $ in Millions	Oct. 23, 2023 USD ($) installment
Settled Litigation, Non-Contingent Payments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	$ 12.8
Number of annual installments | installment	3
Settled Litigation, Non-Contingent Payments | First Installment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	$ 5
Settled Litigation, Non-Contingent Payments | Second Installment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	5
Settled Litigation, Non-Contingent Payments | Third Installment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	2.8
Settled Litigation, Contingent Payments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Settlement agreement	$ 21.3
Number of annual installments | installment	5

PREFERRED AND COMMON STOCKHOL_3

PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Nov. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Preferred stock authorized (in shares)		5,000,000	5,000,000
Preferred stock, par value (in dollars per share)		$ 0.01	$ 0.01
Preferred stock outstanding (in shares)		0	0
Common stock authorized (in shares)		150,000,000
Common stock, par value (in dollars per share)		$ 0.01	$ 0.01
Underwriting equity offering (in shares)	7,400,000
Share price (in dollars per share)	$ 17
Gross proceeds	$ 126.5
Net proceeds	$ 117.6
Common stock issued (in shares)		91,300,000	89,900,000	81,200,000	80,000,000
Common stock, shares outstanding (in shares)		91,300,000	89,900,000	81,200,000	80,000,000

PREFERRED AND COMMON STOCKHOL_4

PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Shares of Common Stock Issued and Outstanding (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning common stock issued (in shares)	89,900	81,200	80,000
Beginning common stock outstanding (in shares)	89,900	81,200	80,000
Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans (in shares)	1,400	1,300	1,200
Common stock issued for public offering (in shares)	0	7,400	0
Ending common stock issued (in shares)	91,300	89,900	81,200
Ending common stock outstanding (in shares)	91,300	89,900	81,200

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) $ / shares in Units, $ in Millions		12 Months Ended
	Sep. 23, 2021 shares	Dec. 31, 2024 USD ($) day $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Jun. 01, 2023 shares
Share-based Compensation [Line Items]
Options granted (in shares)		0	0	0
2017 Plan
Share-based Compensation [Line Items]
Shares available for grant (in shares)		2,200,000			4,800,000
2012 Purchase Plan
Share-based Compensation [Line Items]
Shares available for grant (in shares)		900,000
Number of additional shares authorized (in shares)	4,000,000
Maximum number of shares per participant per offering period (in shares)	5,000
Options and RSUs | Non-Employee Director
Share-based Compensation [Line Items]
Service period for award vesting (in years)		1 year
RSUs
Share-based Compensation [Line Items]
Vesting rights, average trading days | day		20
Weighted average grant date fair value (in dollars per share) | $ / shares		$ 22.09	$ 23.02	$ 25.78
Fair value of restricted stock units that vested | $		$ 37.9	$ 30.5	$ 31
Unrecognized stock-based compensation expense | $		$ 70.9
Weighted-average period for recognition (years)		2 years
RSUs | Maximum
Share-based Compensation [Line Items]
Service period for award vesting (in years)		4 years
RSUs | Minimum
Share-based Compensation [Line Items]
Service period for award vesting (in years)		3 years
RSUs | Achievement levels based on EPS Targets
Share-based Compensation [Line Items]
Vesting weight (in percent)		34%
RSUs | Relative Total Stockholders Return
Share-based Compensation [Line Items]
Vesting weight (in percent)		33%
RSUs | Performance based on Nasdaq Healthcare Provider Index
Share-based Compensation [Line Items]
Vesting weight (in percent)		33%

STOCK-BASED COMPENSATION - Sche

STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) shares in Millions	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Number of shares
Options outstanding, beginning (in shares) | shares	0.7
Options outstanding, ending (in shares) | shares	0.7
Options exercisable (in shares) | shares	0.5
Options vested and expected to vest (in shares) | shares	0.2
Weighted average exercise price
Options outstanding, beginning (in dollars per share) | $ / shares	$ 13.38
Options outstanding, ending (in dollars per share) | $ / shares	13.38
Options exercisable (in dollars per share) | $ / shares	13.38
Options vested and expected to vest (in dollars per share) | $ / shares	$ 13.38
Weighted average remaining contractual life (years)
Options outstanding, Weighted average remaining contractual life (in years)	2 years 7 months 13 days
Options exercisable, Weighted average remaining contractual life (in years)	2 years 7 months 13 days
Options vested and expected to vest, Weighted average remaining contractual life (in years)	2 years 7 months 13 days

STOCK-BASED COMPENSATION - Sc_2

STOCK-BASED COMPENSATION - Schedule of Restricted Stock Units Activity (Details) - RSUs - $ / shares shares in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Number of shares
RSUs unvested and outstanding, beginning (in shares)	4.4
RSUs granted (in shares)	2.7
RSUs vested (in shares)	(1.6)
RSUs canceled (in shares)	(0.2)
RSUs unvested and outstanding, ending (in shares)	5.3	4.4
Weighted average grant date fair value
RSUs unvested and outstanding, beginning (in dollars per share)	$ 24.37
RSUs granted (in dollars per share)	22.09	$ 23.02	$ 25.78
RSUs vested (in dollars per share)	22.98
RSUs canceled (in dollars per share)	23.58
RSUs unvested and outstanding, ending (in dollars per share)	$ 23.66	$ 24.37

STOCK-BASED COMPENSATION - Sc_3

STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	$ 49.8	$ 40.7	$ 38.1
Cost of revenue
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	1.6	1.4	1.7
Research and development expense
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	8.8	4	5.2
Sales and marketing expense
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	9	7.2	6.2
General and administrative expense
Share-Based Compensation Expense [Line Items]
Total stock-based compensation expense	$ 30.4	$ 28.1	$ 25

STOCK-BASED COMPENSATION - Sc_4

STOCK-BASED COMPENSATION - Schedule of Aggregate Intrinsic Value (Details) $ in Millions	Dec. 31, 2024 USD ($)
Share-based Compensation [Line Items]
Aggregate intrinsic value of options outstanding	$ 0.2
Aggregate intrinsic value of options fully vested	0.2
RSUs
Share-based Compensation [Line Items]
Aggregate intrinsic value of RSUs outstanding	$ 71.7

STOCK-BASED COMPENSATION - Sc_5

STOCK-BASED COMPENSATION - Schedule of Shares Purchased and Compensation Expenses for ESPP (Details) - 2012 Purchase Plan - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation [Line Items]
Shares purchased under the plan (in shares)	0.4	0.4	0.3
Plan compensation expense	$ 2.1	$ 2.2	$ 1.9

STOCK-BASED COMPENSATION - Sc_6

STOCK-BASED COMPENSATION - Schedule of Valuation Assumptions for ESPP (Details) - 2012 Purchase Plan	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Valuation Assumptions
Risk-free interest rate	5.30%	5.10%	1.40%
Expected dividend yield	0%	0%	0%
Expected life (in years)	6 months	6 months	6 months
Expected volatility	50%	56%	53%

INCOME TAXES - Schedule of Inco

INCOME TAXES - Schedule of Income Tax Benefit (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current:
Federal	$ 3.4	$ 3.4	$ (0.5)
State	1.5	1.8	1.9
Foreign	1.2	0.2	0.5
Total current	6.1	5.4	1.9
Deferred:
Federal	(15.5)	(51.8)	(25.8)
State	(5.5)	(5.2)	(4.8)
Foreign	3.1	0.1	(2.9)
Change in valuation allowance	15.6	52.6	3
Total deferred	(2.3)	(4.3)	(30.5)
Total income tax expense (benefit)	$ 3.8	$ 1.1	$ (28.6)

INCOME TAXES - Schedule of Loss

INCOME TAXES - Schedule of Loss Before Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income (loss) before income taxes:
United States	$ (125.4)	$ (263.2)	$ (141.3)
Foreign	1.9	1	0.7
Loss before income tax	$ (123.5)	$ (262.2)	$ (140.6)

INCOME TAXES - Schedule of Diff

INCOME TAXES - Schedule of Differences Between Statutory Federal Income Tax Rate and Income Taxes Reported (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Effective Income Tax Rate Reconciliation, Amount
Federal income tax benefit at the statutory rate	$ (25.9)	$ (54.9)	$ (29.5)
State income taxes, net of federal benefit	(2.4)	(4.1)	(3.3)
Research and development credits	(0.4)	(1.6)	(3.5)
Uncertain tax positions	2.8	3.7	0.6
Stock-based incentive awards	0.8	1.2	2.5
Foreign rate differential	3.3	(0.4)	0
Change in valuation allowance	15.7	52.6	2.6
Non-deductible officer compensation	3.9	3	3.5
Acquisitions and dispositions	5.1	0.1	(0.1)
Other, net	0.9	1.5	(1.4)
Total income tax expense (benefit)	$ 3.8	$ 1.1	$ (28.6)
Effective Income Tax Rate Reconciliation, Percent
Federal income tax benefit at the statutory rate	21%	21%	21%
State income taxes, net of federal benefit	1.90%	1.60%	2.30%
Research and development credits	0.30%	0.60%	2.50%
Uncertain tax positions	(2.30%)	(1.40%)	(0.40%)
Stock-based incentive awards	(0.60%)	(0.50%)	(1.80%)
Foreign rate differential	(2.70%)	0.20%	0%
Change in valuation allowance	(12.70%)	(20.10%)	(1.80%)
Non-deductible officer compensation	(3.20%)	(1.10%)	(2.50%)
Acquisitions and dispositions	(4.10%)	0%	0.10%
Other, net	(0.70%)	(0.70%)	0.90%
Total income tax expense (benefit)	(3.10%)	(0.40%)	20.30%

INCOME TAXES - Schedule of Comp

INCOME TAXES - Schedule of Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Net operating loss carryforwards	$ 62.7	$ 77.1
Stock compensation expense	6.6	5
Research and development credits	20.6	20.8
Lease liability	24.4	28
Capitalized research and development costs	54.3	38.4
Accrued expenses and liabilities	16.5	22.5
Other, net	0	3.2
Total gross deferred tax assets	185.1	195
Less valuation allowance	(111.9)	(95)
Total deferred tax assets	73.2	100
Deferred tax liabilities:
Intangible assets	55.5	84.2
Lease right-of-use assets	13.3	15.5
Property, plant and equipment	3.2	1.9
Other, net	0.8	0
Total deferred tax liabilities	72.8	101.6
Net deferred tax asset (liability)	$ 0.4
Net deferred tax asset (liability)		$ (1.6)

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Loss Carryforwards [Line Items]
Deferred tax asset	$ 0.4
Unrecognized tax benefits	51.7	$ 48.1	$ 43.9	$ 32.1
Gross increases - current year tax positions	1	0.8	12.9
Decrease in unrecognized tax benefits within the coming year	48
Unrecognized tax benefits, if recognized, would affect the effective tax rate	$ 32.7	$ 30.2
Revision of Prior Period, Adjustment
Operating Loss Carryforwards [Line Items]
Gross increases - current year tax positions			$ 12

INCOME TAXES - Schedule of Net

INCOME TAXES - Schedule of Net Operating Loss and Research Credit Carryforwards (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($)
Federal | Federal
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 32.2
Net operating loss subject to sections 382,383	Yes
Federal | Federal | Capital loss
Operating Loss Carryforwards [Line Items]
Tax credit	$ 13.8
Tax credit subject to sections 382,383	No
Federal | Federal | Research credit
Operating Loss Carryforwards [Line Items]
Tax credit	$ 10.5
Tax credit subject to sections 382,383	Yes
State | Utah
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 0.9
Net operating loss subject to sections 382,383	No
State | Utah | Research credit
Operating Loss Carryforwards [Line Items]
Tax credit	$ 4.9
Tax credit subject to sections 382,383	No
State | California
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 5
Net operating loss subject to sections 382,383	Yes
State | California | Research credit
Operating Loss Carryforwards [Line Items]
Tax credit	$ 5.2
Tax credit subject to sections 382,383	No
State | Other
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 6.3
Net operating loss subject to sections 382,383	Yes
Foreign
Operating Loss Carryforwards [Line Items]
Net operating loss	$ 4.3
Net operating loss subject to sections 382,383	No

INCOME TAXES - Schedule of Unre

INCOME TAXES - Schedule of Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Unrecognized Tax Benefits
Unrecognized tax benefits at the beginning of period	$ 48.1	$ 43.9	$ 32.1
Gross increases - current year tax positions	1	0.8	12.9
Gross increases - prior year tax positions	2.6	3.6	1.6
Gross decreases - prior year tax positions	0	(0.2)	(2)
Gross decreases - settlements	0	0	(0.7)
Unrecognized tax benefits at end of year	51.7	48.1	43.9
Interest and penalties in year-end balance	$ 8.8	$ 6.4	$ 4.1

LEASES - Narrative (Details)

LEASES - Narrative (Details) ft² in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) ft²	Dec. 31, 2023 USD ($)
Lessee, Lease, Description [Line Items]
Total future lease payments	$ 141.7
Lease termination accrual	3.8	$ 4.4
Lease cost	21	25.9
Variable lease expense	$ 5	3.5
Operating lease weighted average remaining lease term	9 years 3 months 18 days
Operating lease weighted average discount rate	6.50%
West Salt Lake City
Lessee, Lease, Description [Line Items]
Additional area of real estate property | ft²	63
Lease term (in years)	12 years
Total future lease payments	$ 18.2
Salt Lake City
Lessee, Lease, Description [Line Items]
Reduction in operating lease, right-of-use assets		6.4
Reduction in operating lease liability		$ 6.4
Minimum
Lessee, Lease, Description [Line Items]
Remaining lease terms	1 year
Maximum
Lessee, Lease, Description [Line Items]
Remaining lease terms	14 years

LEASES - Schedule of Maturities

LEASES - Schedule of Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Maturities of operating lease liabilities
2025	$ 18.9
2026	12.3
2027	12.3
2028	12.4
2029	12.1
Thereafter	73.7
Total future lease payments	141.7
Less: amounts representing interest	41
Present value of future lease payments	100.7
Less: current maturities of operating lease liabilities	(12.8)	$ (16.2)
Noncurrent operating lease liabilities	$ 87.9	$ 97.4

EMPLOYEE DEFERRED SAVINGS PLA_2

EMPLOYEE DEFERRED SAVINGS PLAN - Narrative (Details)	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Company matching contribution as percentage of employee contribution	50%
Employer matching contribution, percent of employee's compensation	4%

EMPLOYEE DEFERRED SAVINGS PLA_3

EMPLOYEE DEFERRED SAVINGS PLAN - Schedule of Contributions to the Plan (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Retirement Benefits [Abstract]
Deferred savings plan contributions	$ 10.3	$ 10	$ 9

SEGMENT AND RELATED INFORMATI_3

SEGMENT AND RELATED INFORMATION - Narrative (Details)	12 Months Ended
	Dec. 31, 2024 segment
Segment Reporting [Abstract]
Number of operating segments	1

SEGMENT AND RELATED INFORMATI_4

SEGMENT AND RELATED INFORMATION - Schedule of Assets by Geographical Region (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 729.5	$ 832.9
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	728.1	794.6
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets	$ 1.4	$ 38.3

BUSINESS ACQUISITION - Narrativ

BUSINESS ACQUISITION - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Gain on acquisition	$ 2.2	$ 0	$ 0

DIVESTITURE (Details)

DIVESTITURE (Details) - Disposed of by Sale - EndoPredict - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Aug. 01, 2024
Disposal of Subsidiary [Line Items]
Sale of business for net cash consideration		$ 10
Loss on divestiture	$ (12.4)
Foreign currency translation	$ 4.4

SUPPLEMENTAL CASH FLOW INFORM_3

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Supplemental Cash Flow Elements [Abstract]
Cash paid for income taxes	$ 2.7	$ 1.9	$ 1.8
Cash paid for interest	1.9	1.4	0
Change in operating lease right-of-use assets and lease liabilities
Operating lease right-of-use assets	3.1	(31)	46.9
Operating lease liabilities	(3.1)	36.7	(46.9)
Tenant improvement allowance not yet received	0	0	22.9
Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities	$ 6.4	$ 6.9	$ 10